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Abstract
Abstract
Malaria is a parasite with a complex lifecycle, and commonly used anti-
malarial agents from the artemisinin family have varied effectiveness
over different stages of this lifecycle. The pharmacokinetic profile of
the artemisinins is also strongly influenced by the parasite burden and
lifecycle stage. This work introduces a new pharmacokinetic and phar-
macodynamic model incorporating these interdependent drug and life-
cycle features, for orally administered artesunate and its principal meta-
bolite dihydroartemisinin.
This model, like the underlying system whose features it attempts to
capture, is quite complex and cannot be solved analytically like stand-
ard linear first-order compartmental models previously used for pharma-
cokinetic modelling of these drugs. Therefore, understanding, inference
and validity are explored through use of the modern statistical technique
of a Sequential Monte Carlo sampler. Structural, numerical and practical
identifiability are important concepts for all models, the latter two espe-
cially so in this case as the model structure does not admit an algebraic
structural identifiability analysis. Motivated by this, the above identifi-
ability concepts are also investigated in connection with the Sequential
Monte Carlo technique.
Sequential Monte Carlo is demonstrated to be a useful tool for gaining
insight into models whose structural identifiability is not known, just as
it is also shown to have significant advantages in parameter inference
over the classical approach.
xiv
Abstract
The coupled parasite lifecycle and artemisinin-derivative model is
built in stages, starting with an in vitro submodel capturing the dy-
namics of uptake of artemisinins into parasitised and non-parasitised red
blood cells. Next, the parasite lifecycle, or ‘ageing’ model, is introduced,
which uses a new concept of shadow compartments to achieve its aims
of describing ageing in continuous time and to exhibit sufficient con-
trol over the parasite population. Finally, these models are integrated
together into the full coupled pharmacokinetic and pharmacodynamic
model. More work is needed to fully assess the resultant model on clin-
ical datasets, but the building blocks upon which it was constructed
appear to fulfil their aims reasonably well.
xv
1. Introduction
Chapter 1
Introduction
1.1. Background
A brief overview of the background of this work is presented here, so that
the aims and objectives can be stated and understood. More details on
each aspect is given in the dedicated background and literature chapter
following this one, chapter 2.
Plasmodium falciparum malaria: Plasmodium falciparum is the
most deadly of the parasites that cause a severe blood disease known
as malaria in humans. Infection starts when an infected Anopheles mos-
quito carrying sporozoites injects those sporozoites into the subject while
taking a blood meal. Initially the sporozoites develop in the liver, and
after some time release merozoites to begin the blood stage of the life-
cycle. In this blood stage, which is the symptomatic stage, the parasite
has a complicated lifecycle of approximately 48 hours, beginning with
the invasion of red blood cells (RBCs) and ending when the RBCs burst
to release more morozoites into the blood stream ready to invade again.
Some merozoites develop into gametocytes, ready to picked up by another
mosquito taking a blood meal later, where they further develop and rep-
licate into sporozoites, from whence they can infect the next person. See
section 2.1 for more information.
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Artemisinins / artesunate and dihydroartemisinin: Arte-
sunate (ARS) and dihydroartemisinin (DHA) are from the artemisinin
class of anti-malarial compounds. These are important anti-malarials be-
cause they work rapidly and effectively, have good safety characteristics,
and limited resistance to these compounds has developed so far. ARS
is water-soluble and thus easy to administer, and is rapidly metabolised
into DHA, which is therefore responsible for most of the anti-malarial
action.
The pharmacokinetics and pharmacodynamics (defined next) of these
compounds are thought to vary significantly based on the stage of the
parasites within their lifecycle, and the resistance that the parasites have
developed to the medication is again thought to manifest most promin-
ently in a limited period of the lifecycle. The details of these stage-specific
effects are given in section 2.2.
Pharmacokinetics (PK): Pharmacokinetics is the study of the time
course of the movement and changes to a substance (typically a drug)
after it enters the body. This encompasses the absorption, distribution,
metabolism and elimination of the substance. In a quantitative sense,
pharmacokinetics of a substance are often described through a mathem-
atical model such as a compartmental model. In such a model, the body
is represented in a simplified manner as a number of connected functional
compartments, where the kinetic behaviour in each individual compart-
ment is considered identical for all molecules of the drug represented as
being lumped into that compartment.
Pharmacodynamics (PD): Pharmacodynamics, on the other
hand, is the study of the effect on the body resulting from a specific
substance. Pharmacodynamics is tightly coupled with the concept of
pharmacokinetics since the amount of substance in a particular location
in the body is the biggest influence on the effect that the substance has
in that location.
Details on the modelling techniques and assumptions present therein
2
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are described in section 2.4.
Pharmacometrics: The term pharmacometrics refers to pharma-
cokinetics, pharmacodynamics and other mathematical methods of ana-
lysis and interpretation of drug data.
Structural, numerical and practical identifiability: Once a
mathematical model has been developed, values need to be assigned to
its parameters. The goal is to find parameter values such that the model
does a good job of describing real data. However, this is not necessarily
a well-posed problem: even in a setting of perfect error-free data, there
may be multiple (even uncountably many) parameter values that provide
equivalent observable model behaviour, usually with quite different im-
plications for model predictions of unobserved behaviour. This situation
is known as structural unidentifiability if there are uncountably many
such values or structural local identifiability if there are countably many.
The converse is known as structural global identifiability. In the structur-
ally non-global situations, the data alone (even if perfect and error-free
as is assumed) is incapable of discriminating between the various pre-
dictions. This may mean that one or more desired outcomes from the
model may instead have to be applied as assumptions in the modelling
process, rather than informing on and providing evidence for those as-
pects. Alternatively, it may be necessary to modify the model and/or
the data collected so that parameters of interest are instead structurally
identifiable, which may then potentially permit collection of evidence for
or against the desired outcome.
However, even if a model is structurally (globally) identifiable — and
can be shown to be so (often this is very challenging to demonstrate) —
it does not necessarily follow that the parameters can be reliably determ-
ined under the non-perfect conditions of discrete observations, especially
where those observations are also made with uncertainty/error. The
terms numerical (un)identifiability have been adopted in this thesis to
describe the situation in this context, where it is known that the model
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is perfectly capable of describing the underlying data (e.g. because it has
been tested against synthetic data generated using the model).
Finally, when dealing with real data where the model is unlikely to be
a perfect description of the underlying experimental system, the problem
is known herein as the practical identifiability problem. More detail on
these identifiability aspects is provided in section 2.5.
1.2. Aims and objectives
The main aim of this work was to develop, analyse and validate a mechan-
istic model coupling artesunate and dihydroartemisinin pharmacokinetics
with the corresponding pharmacodynamics, that can account for effects
that are specific to certain stages of the malaria parasite lifecycle.
Such a model would ideally:
1. be capable of describing in vivo and (mutatis mutandi) in vitro
pharmacokinetics and pharmacodynamics on an individual level,
with the potential to do the same on a population level;
2. provide reasonable prediction of dynamics that cannot be measured
or observed;
3. be able to reproduce or confirm current knowledge or hypotheses
regarding stage specific action and the effect of resistance;
4. be suitable for estimating the effect of different dosing regimens;
5. be able to identify or confirm, and simulate the effect of, potential
improvements to treatments;
6. be relatively simple and easy to follow/use;
7. be free of jumps in the time course predictions and observations;
and the analysis would ideally include:
4
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1. showing the model to be structurally identifiable (preferably glob-
ally so), as well as numerically and practically identifiable;
2. obtaining Bayesian posterior distributions of model parameters, for
various subjects/in vitro studies and/or synthetic data;
3. determining the sensitivity of the model to the parameters.
This will therefore necessitate an exploration of the current methods
available for analysing models for structural identifiability and determin-
ation of their suitability for the developed non-linear model with switch-
ing behaviour. Such structural identifiability methods may need to be
adjusted and implemented.
As part of the statistical analysis and parameter inference, it will be
necessary to implement a Monte Carlo method to cope with the high-
dimensional situation and the complicated model. In particular, it is
intended to implement a Sequential Monte Carlo (SMC) sampler. This
class of samplers are still somewhat computationally demanding but have
the advantages that they can be tested for convergence in a simple way
and that the parameters do not need to be precisely tuned to behave
reasonably. Of course, there is an element of tuning but essentially,
given enough particles, enough iterations and enough runs, and a sensible
proposal distribution, a good approximation of the posterior distribution
will be obtained. Such samplers have apparently been used only rarely in
these situations to date, so it will also be helpful to use an SMC sampler
on simpler models to understand the behaviour and limitations of the
method and situations to be aware of.
1.3. Structure of this thesis
Chapter 2 introduces the application area of malaria and motivates in-
vestigation of the artemisinin class of anti-malarial drugs. Background
material is provided on the modelling and analysis techniques used later
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in the thesis, including the important concept of structural identifiab-
ility, and some methods for conducting such a structural identifiability
analysis, and a discussion of the difficulties that may arise in attempting
to carry out such an analysis. Related forms of analysis known as nu-
merical and practical identifiability analyses are also introduced, which
complement a structural identifiability analysis and can suggest different
angles for attacking the structural identifiability analysis if it has not
been possible or straightforward to solve directly.
The specific pharmacokinetic, in vitro, and pharmacokinetic/phar-
macodynamic datasets used in this thesis are introduced, as are existing
models with similar aims to this work in summarised format.The phar-
macokinetic model from Hall [1] is also presented again as it is revisited
here.
A Sequential Monte Carlo method is introduced in subsubsec-
tion 2.7.6.1 for the purposes of parameter inference and for determining
numerical and practical identifiability. This method is then applied to a
low-dimensional model with known posterior distribution, and the out-
put compared with that known posterior, and then also applied to the
pharmacokinetic model.
In section 4.2, a new pharmacokinetic/pharmacodynamic model is
then introduced, with some discussion on its behaviour and properties.
Finally, section 5.1 outlines the further work relevant to the model that
would ideally be conducted if time and funding permitted.
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Chapter 2
Background and literature
review
2.1. Malaria
Malaria is an extremely burdensome disease caused by micro-parasites
with asexual lifecycles, and is transmitted via Anopheles mosquitoes as
vectors. There are 5 malaria parasite species (Plasmodium) that can in-
fect humans, and together they continue to infect hundreds of millions of
people every year, with 3.2 billion people being considered “at risk” by
the World Health Organisation. It is still a major killer in parts of the
world, despite recent efforts having some success in reducing mortality
rates [4]. Even where malaria does not cause death it is still has a severe
effect on those infected, and on the health care systems and socioeco-
nomics of the countries and communities where the most vulnerable live
[5, 6].
Young children are the most severely affected, with malaria having
killed nearly half a million African children in 2013 before they turned
five (equivalent to approximately one death every minute) [7]. Indeed,
malaria is the cause of 15% of deaths of children under five in parts of
Africa [7].
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Malaria is (currently) an entirely preventable disease, with a single
bed net (if used appropriately) providing an effective barrier from mos-
quito bites for a few years, spraying indoor insecticide is effective for
many months, and prophylactic medicines are available. There are also
recent hopes concerning malaria vaccines [8]. Many treatments are also
available for malaria, which are often effective if they can be administered
to patients in reasonable time. However, resistance to malaria treatments
has been detected in many regions and is a major concern [9]. If new
treatments cannot be introduced, and current treatments rendered more
effective, both as a matter of urgency, then controlling malaria even to
the same extent as currently will cease to be possible, and the unpleasant
statistics presented above will only get worse.
The most deadly malaria species in humans is Plasmodium falciparum
[4], and is the species focussed on in this work. After an initial phase
in the liver, the parasites emerge into the blood stream and, from there,
undergo a 48 hour lifecycle, depicted in Figure 2.1. It is in the blood
stage that symptoms begin and this work concentrates on this blood
stage, which tends to synchronise in vivo, i.e. with the majority of para-
sites simultaneously at similar stages in their lifecycles [10]. The parasite
blood stage lifecycle starts with the invasion of red blood cells, from
whence maturation begins. The parasites are seen to have a ring-shape
for the first 12 hours or so, and these 12 hours are divided into “early”
and “late” ring stages. For the next 12 hours, the parasites are said
to be in the young trophozoite stage, and they begin to multiply into
around 5–32 (mean 20) new daughter parasites called merozoites [11, 12,
13]. After this 12 hour period, the parasites become mature trophozoites,
whereupon the infected red blood cells sequester in the organs to avoid
clearance by the spleen [14], meaning that they do not circulate around
the body with the remainder of the blood. Therefore, they cannot be
detected in blood drawn from patients in the usual way. After the next
12 hours, known as the schizont phase, the cells burst and release the
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merozoites into the blood stream to start the cycle afresh, but with po-
tentially fewer red blood cells available for re-invasion. It is this bursting
phase of the lifecycle that causes most symptoms [15], though the se-
questration in organs can also reduce blood flow to those organs which
can cause more severe symptoms [16].
The causes of transition from uncomplicated to severe malaria are not
well understood [12]; it is not as simple as developing a high parasitaemia
[17]. People in endemic areas are more likely to have gradually developed
resistance over repeated exposure [18] and so are not affected by high
parasitaemias in the same way as those from non-endemic areas [17].
Non-immune individuals might show symptoms with a parasite load of
10 per microlitre of blood, while partly immune individuals will not show
symptoms unless the load reaches 1,000 parasites per microlitre of blood
[19].
Plasmodium falciparum parasites are most metabolically active dur-
ing the mature ring stage of their lifecycle, and this explains why many
of the drugs for treating malaria are most effective against this stage [20].
The next subsection describes the class of anti-malarials of most interest
here, Artemisinins.
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N Figure 2.1: Main blood stages of the Plasmodium fal-
ciparum malaria parasite lifecycle and their
durations
2.2. Artemisinins
Although also used for other species of malaria and even different pur-
poses altogether, the artemisinin class of compounds is highly effective
against at least parts of the blood stage of Plasmodium falciparum and
have been used with increasing frequency since the 1990s [21]. Artemisin-
ins are generally recommended to be administered together with a con-
comitant drug with a different mechanism and a longer duration of ac-
tion in an effort to delay resistance [9]. Such treatments are known as
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artemisinin-based combination therapies and are the most effective an-
timalarials available today [22, 23]. As such, they are the treatment
recommended by the World Health Organisation for many classes of pa-
tient [9].
Artemisinins alone are the most rapidly acting of all current antimal-
arial drugs [24] and are able to reduce the parasite biomass ∼10,000-fold
per asexual life cycle [25]. Combined with their wide tolerance, it is clear
to see that artemisinins are incredibly important to malaria control and
treatment efforts. However, this class of anti-malarials have also shown
waning efficiency in parts of South-East Asia [4], thought to be due to
malarial resistance to the compounds affecting the associated pharmaco-
dynamics in the early stages of the parasite lifecycle [26].
Artemisinin drugs distribute into red blood cells, primarily infected
ones, and this is where their anti-malarial action is thought to occur.
However, debate remains concerning the exact mechanism of action of
these compounds [27, 28, 29]. The general theory is that iron accumulates
in red blood cells which have been infected by malaria parasites, which
then react with the artemisinin compounds, forming free radicals which
in turn damage the parasites [30], although a number of unanswered
questions remain [31]. The accumulation of artemisinins in parasitised
red blood cells may therefore play an important part in their potency
[24]. This suggests that the pharmacokinetics of the drug will differ
vastly between healthy individuals and malaria patients, which is indeed
found to be the case [32], though the degree of severity of the malaria
infection appears to be less important [33]. However, the blood plasma
concentration–time profiles and thus the pharmacokinetics of artemisin-
ins have been shown to display high inter-individual variability in many
studies, even after accounting for many covariates such as baseline para-
sitaemia, age, body weight and gender [34], and this variability increases
in malaria patients compared to healthy volunteers [35].
Artemisinins are effective throughout a wide period of the parasite
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lifecycle [26], though the effectiveness varies throughout that lifecycle
[31, 36], especially where resistance has emerged [26, 37]. It is also likely
that different derivatives are affected by resistance to differing extents
[38].
Further understanding of the pharmacokinetics and pharmacodynam-
ics of artemisinins may assist in informing more effective dosing regimens,
discovering more about the effects of resistance, as well as in developing
new or complementary antimalarials or artemisinin derivatives with de-
sirable properties.
Artesunate (hereafter ARS) is the most frequently used artemisinin
derivative, and is rapidly and almost entirely converted to di-
hydroartemisinin (hereafter DHA) in vivo, mostly by plasma esterases
and liver cytochrome P450 CYP2A6 [39, 40, 41]. DHA is the most act-
ive of all major artemisinin derivatives, with activity approximately 1.4
times that of ARS [42].
ARS is water soluble, facilitating its absorption [43] (usually assumed
to be fast, efficient and first-order [39]). Although it is rapidly hydro-
lysed into DHA, it may still make a significant contribution to parasite
kill [44]. DHA is also rapidly eliminated from plasma, again either due
to accumulation in infected red blood cells or through further metabol-
ism (e.g. glucuronidation [45]), but the metabolites of DHA are inactive
[46]. Although ARS and DHA are rapidly eliminated from plasma, anti-
malarial effect is observed to continue for some time after decline of both
ARS and DHA plasma concentrations to ineffective levels [47].
2.3. Data
It is important when designing a model to consider the data that are
available to calibrate or otherwise verify the model. A model that is
too ambitious will not be supported by the data, while a model that
is too simplistic may not be able to relate to the data in full, or may
12
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not reproduce some of the observed features of the data. Therefore, an
overview of the available data is provided now, before any models or
modelling techniques are discussed.
Two in vivo datasets have been made available for use in this thesis.
One consists of pharmacokinetic data only, and will be referred to as
the Mahidol_PK dataset. This dataset was also used in Hall [1] and
Hall et al. [2]. The other, corresponding to a different study, contains
pharmacokinetic and pharmacodynamic data, and will be referred to as
the MORU_ARC3_PD dataset.
Additional data were extracted from Vyas et al. [48] and are also
presented here.
2.3.1. Mahidol_PK dataset
The Mahidol_PK dataset consists of 19 malaria patients from a study
carried out at the Department of Clinical Tropical Medicine, Faculty of
Tropical Medicine, Mahidol University, Bangkok, 10400, Thailand. Pa-
tients were selected based on a diagnosis of adult non-severe P. falciparum
malaria with a parasite count less than 10,000 parasites per microlitre of
blood. The patients were each administered 2mg/kg artesunate in frac-
tions of 50mg oral tablets (body weights not part of the dataset provided
to the author) twice daily for three days, in combination with 1800mg
fosmidomycin and 750mg azithromycin which are antibiotics and not con-
sidered relevant to the modelling (described later). Food was restricted
for the first hour after dosing.
The data consist of ARS and DHA concentrations (provided in units
of ng/ml but converted to nmol/l prior to analysis) from assayed blood
plasma samples over a time course of 12 hours. Blood plasma samples
were drawn from the patients immediately after administration of the
first dose on the first day, 15 minutes after, 30 minutes after, 1 hour after,
1.5 hours after, 2 hours after, 3 hours after, 4 hours after, 6 hours after,
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8 hours after and 12 hours after administration of the first dose on the
first day. No samples were taken for subsequent doses or on subsequent
days and so cannot be included in the modelling.
Samples were analysed to determine their ARS and DHA concen-
trations using tandem liquid chromatography-mass spectrometry (on a
Thermo Fisher Quantum Access Triple Quad Mass Spectrometer) based
on the assay described in Hanpithakpong et al. [49]. (The individual
samples were analysed only once but assay robustness was confirmed by a
re-analysis of approximately 10% of all samples. Analytical runs included
a full calibration curve and three replicate quality control samples.) The
assay has an associated lower limit of quantification (LLOQ) for each
analyte and passed Food and Drug Administration (FDA) validation,
for which the requirement is to measure quality control samples and
standard curve samples with known concentrations above the respective
LLOQ to within ±15% of the nominal value. Specifically, the coefficient
of variation for the assay is 15% for both analytes. Values below the
respective LLOQ may have significantly greater relative uncertainty or
noise. The LLOQ for ARS was LLOQ1 = 3.9 nmol/l and that of DHA
was LLOQ2 = 22.9 nmol/l. The assumption is that values reported for
unknown samples above the respective LLOQ will also be within 15% of
the actual value. Observations below the respective LLOQ are felt to be
so unreliable that such values are not quantified; they are only reported
as being below the limit of quantification (BLQ). In this way, 41% of the
ARS data and 8% of the DHA data are censored.
Note that over the 12 hour time span for a single subject, a wide
range of drug concentrations was observed, most particularly for DHA.
Specifically, for DHA, concentrations smaller than the LLOQ and con-
centrations above 6, 000 nmol/l were recorded for some patients over the
course of the sampling interval. In common with other studies, there was
also wide variability between patients in terms of the concentration–time
profiles for both ARS and DHA.
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The majority of the patients had peak ARS concentrations within 1.5
hours after drug administration (74%), and peak DHA concentrations
within 2 hours (63%). However, it was already clear from the data that
over half of the patients experienced delayed or possibly double peaks
in the concentration–time profiles for both ARS and DHA. These are
not thought to be outliers due to the assay validation, and the pattern
is quite consistent in some individuals. There are no covariates with
these data to allow further analysis and the cause of this phenomenon is
not known, nor the frequency of incidence in other artesunate studies as
individual patient profiles are often not discernible. This issue does not
appear to be widespread or well known in relation to artemisinin drugs,
but has been reported with the derivative artemether, which was found
by Van Agtmael et al. [50] to have a biphasic absorption profile. As the
mechanistic cause of the phenomenon is unknown, the differences in the
absorption process have not been accounted for in the present model.
This indicates that the model is misspecified and will not be suitable
for all the patients, though it is hoped that it will still be applicable
for many of the patients. The patients were therefore divided into two
groups, one where the concentration–time profiles for both ARS and DHA
exhibited only a single peak each within the expected time after drug
administration, and the other group for the remaining patients where the
absorption profile was unexpected, e.g. being slower to reach the peak
concentrations, having multiple peaks and/or having delayed elimination.
2.3.2. In vitro uptake data
Vyas et al. [48] have conducted radio-labelled in vitro experiments to
assess the rate, extent and reversibility of uptake of artemisinin into
Plasmodium falciparum parasitised and non-parasitised red blood cells.
They incubated radio-labelled artemisinin in blood for set times under
controlled experimental conditions, varying these conditions to invest-
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igate the effect of haematocrit, parasitaemia, temperature, artemisinin
concentration and incubation time on the extent of uptake into red blood
cells. After incubation, they separated (centrifuged) the red blood cells
(precipitate/pellent) from the plasma (supernatant) and counted the dis-
integrations per minute from each. The partitioning fraction was then
calculated as the ratio of the number of disintegrations per minute from
the pellent compared to the total number of disintegrations per minute,
and thus shows the degree of uptake of the artemisinin into the red blood
cells.
They used their results to conclude that artemisinin diffused passively
and reversibly across the red blood cell membrane for uninfected cells,
but that uptake was higher, saturable and irreversible in infected red
blood cells, supporting the belief that the process is carrier mediated.
Their quantitative experimental results were presented in graphical
format, showing the uptake into the red blood cells under the various
experimental conditions. Some of these results have been extracted from
the graphs to facilitate use in models in this work, and are presented in
Table 2.1. Results obtained below body temperature (37°C) are not of
interest here and have not been extracted.
Although these results concern artemisinin itself, rather than arte-
sunate or dihydroartemisinin which are of interest here, there are no
known available data for the latter two derivatives, and because they are
from the same family, it will be assumed that they behave similarly.
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Experimental conditions Observation
initial
artemisinin
concentra-
tion
(nM)
parasitaemia
(fraction)
hematocrit
(fraction)
incubation
time
(hours)
partition in
pellet
(fraction)
880 0 0.1 2 0.20
880 0 0.2 2 0.28
880 0 0.33 2 0.39
880 0 0.44 2 0.48
880 0.06 0.1 2 0.38
880 0.06 0.2 2 0.52
880 0.06 0.33 2 0.62
880 0.06 0.44 2 0.67
1,410 0.07 0.33 0.083 0.33
1,410 0.07 0.33 0.167 0.36
1,410 0.07 0.33 0.333 0.39
1,410 0.07 0.33 0.5 0.46
1,410 0.07 0.33 0.75 0.50
1,410 0.07 0.33 1 0.54
1,410 0.07 0.33 2 0.55
1,410 0.07 0.33 3 0.54
1,410 0 0.33 0.083 0.30
1,410 0 0.33 0.167 0.30
1,410 0 0.33 0.333 0.32
1,410 0 0.33 0.5 0.32
1,410 0 0.33 0.75 0.33
1,410 0 0.33 1 0.31
1,410 0 0.33 2 0.34
1,410 0 0.33 3 0.33
880 0.06 0.33 2 0.61
1,060 0.06 0.33 2 0.63
1,230 0.06 0.33 2 0.52
1,410 0.06 0.33 2 0.49
1,760 0.06 0.33 2 0.49
2,110 0.06 0.33 2 0.44
2,820 0.06 0.33 2 0.40
3,520 0.06 0.33 2 0.37
880 0 0.33 2 0.37
1,060 0 0.33 2 0.36
1,230 0 0.33 2 0.35
1,760 0 0.33 2 0.33
2,110 0 0.33 2 0.35
2,820 0 0.33 2 0.36
3,520 0 0.33 2 0.36
Table 2.1: Table of artemisinin in vitro red blood cell up-
take data extracted from Vyas et al. [48]
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2.3.3. MORU_ARC3_PD dataset
A pharmacokinetic, pharmacodynamic dataset including ARS and DHA
concentration-time courses, and parasitaemia and haematocrit time
courses was provided for 80 Plasmodium falciparum patients across two
study sites, 40 patients from each of Wang Pha (Thailand) and Pailin
(Cambodia), which are areas of low transmission intensity. Half of the
patients from each site were randomly assigned to receive 2 mg/kg oral
artesunate every 24 hours for seven days, and the other half received
4 mg/kg oral artesunate for 3 days together with mefloquine (another
anti-malarial agent) on days 3 and 4. The (anonymised) data consist of
artesunate and dihydroartemisinin concentrations (ng/ml converted to
nmol/l, “<LLOQ” or “No Peak”) in blood plasma (not whole blood con-
centrations) and timings thereof (date, hours, mins) at various intervals
over the treatment period, together with parasite counts (per mm3 whole
blood, decimal with varying degrees of accuracy) and timings thereof
(decimal relative to first dose) and haematocrit levels (%, decimal with
varying degrees of accuracy, same timings as parasite counts) during both
the treatment (every 4–8 hours) and follow-up periods. The exact time
and dates (date, hours, mins) and amounts (mg) of artesunate doses were
recorded, as were any adverse events that the patients experienced (e.g. if
patient vomited and needed the drug to be re-administered), symptoms,
concomitant diseases and medications, and previous relevant medication
and comprehensive admission data, including age at time of enrolment,
height, weight, biochemistry, haematology and daily clinical observations
(heart rate, respiratory rate, temperature, etc).
These data were previously used by Dondorp et al. [51] and Saralamba
et al. [37]. Dondorp et al. [51] used these data to conclude that the mal-
aria has reduced in vivo susceptibility to artesunate in Pailin compared to
Wang Pha, corresponding to slower parasite clearance. Saralamba et al.
[37] used these data to support a hypothesis that the resistance mainly
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reduces ring-stage susceptibility, and suggests doubling the frequency of
artesunate dosing to restore the higher parasite clearance rate.
Mefloquine was not described earlier since it is not a focus of this
work, but it is an anti-malarial compound mostly affecting schizonts,
and reaches its peak concentration following a single dose in 17.6 hours
and has a mean elimination half-life of 18.1 days [52]. This is therefore a
much longer-acting compound when compared to the artemisinins and so
is a suitable partner drug for artemisinin combination therapy. However,
unlike the artemisinins, a single dose of mefloquine does not provide
sufficient blood concentrations to achieve a reasonable efficacy, and so
it is normally dosed with a high dose daily for 3 days, and lower doses
thereafter, to reach such a suitable concentration during the third or
forth days [52]. The data for the later days where mefloquine has been
used as a concomitant cannot therefore be directly used to determine the
efficacy of the the artemisinins to schizonts, but it may be possible to
estimate the contribution that the mefloquine made to parasite kill.
2.4. Modelling techniques
In order to extract the most information out of a model, sufficient in-
formation must be incorporated in the design of the model. Namely, in
order to use a model for predictive purposes, knowledge (or predictions)
of the mechanisms used by the system being modelled should be incor-
porated into the model. This is preferable to purely data-driven models,
which lack the same kind of predictive power to answer questions about
what might happen at times beyond the observed range, or with different
inputs or input sites, for example. While a mechanistic model is more
likely to suffer from model mis-specification, data can help discrimin-
ate between candidate mechanistic models and to provide evidence for
or against specific mechanisms. The modelling techniques used in this
work are mechanistic and include a combination of compartmental and
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receptor-ligand type models. For simplicity, all randomness is assumed
to arise from a non-systematic error on the observations; the models
themselves are deterministic.
2.4.1. Compartmental models
(Note that much of the material in this section is adjusted from Hall [1].)
A compartmental system model is made up of a finite number of
• compartments — kinetically homogeneous amounts of material [53,
p. 3] (homogeneous, well-mixed, lumped subsystems [54, p. 1])
(with associated quantities);
• flows — material transfer between compartments and to and from
the environment, including inputs to the system (with associated
flow rates),
• observations — functions of the compartments defining quantities
of which measurements are to be made at least once,
such that the quantities of material within each of the compartments may
be described by a set of coupled first-order ordinary differential equations
[54, p. 1].
By employing compartmental modelling, some key assumptions/sim-
plifications are made:
• mixing of the substance within each compartment is complete (if
not, the flow rates will not always be proportional to the present
value of the concentration [55, p. 60])
• mixing of the substance within each compartment is instantaneous
[55, p. 60].
Note that these assumptions are unlikely to hold in practice, but they
are simplifications which allow easy model formulation and often result
in models which are successful [54].
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Only deterministic compartmental models are considered here. Com-
partmental models involve mass-balance and can be succinctly described
by diagrams, though rate functions and initial conditions usually also
need to be specified, and depending on the number and length of such
expressions, it can be clearer to do so separately from the diagram.
The compartments are typically represented by circles or rectangles,
flows between compartments are represented by simple arrows, and out-
flows from the system which are a special case of flows (elimination flows)
are represented by arrows similarly to flows, but without a receiving
compartment at the end of the arrows. Flows which are linear will be
represented in this thesis by having a single arrowhead, while non-linear
flows will be represented with a double arrowhead. Non-linear flows will
generally be given by the flow rate rather than the flow rate constant.
Inputs to the system will be represented by double-stroke arrows, and
finally, observations will be represented by an eye connected by dashed
lines to any compartments whose quantity or concentration of material
directly forms part of the observation function, unless it would be too
visually distracting to do so.
Throughout, T will denote the time domain of interest, and without
loss of generality will be assumed to start at initial time 0. The quant-
ity of material in compartment i at time t ∈ T is often denoted qi(t)
[56, p. 260] (which therefore has the constraint of being non-negative),
and the flow rate from compartment i to compartment j is denoted by
kj,i(t) (note that conventions for the order of indices of flows rates differ
between the pharmacokinetic literature and elsewhere [54, p. 2]), while
the environment — representing anything external to the system model
— will be denoted by e (some authors use 0 [56, p. 260]).
For linear time-invariant flows, rate constants kj,i are generally shown
instead of flow rates because they simplify the presentation (and in par-
ticular it is easier to fit the information on the model diagram). However,
the notation for rate constants is somewhat abusive: the corresponding
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flow rate at time t is the rate constant times the quantity of material
in the donor compartment at time t, i.e. kj,i(t) = kj,iqi(t), where kj,i(t)
represents an (instantaneous) flow rate, and the constant kj,i in the right
hand side of the equation is a flow rate constant.
This work will use flow rates which are donor-controlled, as well as
flow rates which are not. Donor controlled means that the flow rate is a
function only of the quantity of material in the donor compartment, not
of any other compartments, i.e. the flow rate kj,i(t) from compartment i
to compartment j is a function of qi(t) only: kj,i(t) = f(qi(t)) for some
function f . In the linear flow case, this f is linear, and so admits a
description by a flow rate constant as above. For flow rates that are not
purely donor-controlled, it can be helpful to draw some connection (e.g.
a dashed line) between the flow rate and the controlling quantities, but
in practice this can overwhelm the diagrams.
The most general form of equation for the quantity of material in
compartment i in a non-linear compartmental system, which is derived
on the basis of mass-balance principles, is:
q′i(t) = ki,e(t) +
∑
j
ki,j(t)−
ke,i(t) +∑
j
kj,i(t)
 ,
where the sums are taken over all compartments j 6= i, and any flows
which do not occur have rate function identically 0.
These equations, together with equations for the observation function
y:T → Rm and initial conditions q(0) ∈ Rn, make up the general form
of a compartmental model:

q′(t) = f(q,p,u, t)
q(0) = q0(p)
y(t) = h(q,p, t),
(2.1)
where t ∈ T. f has special properties due to the model’s compartmental
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structure. Here, p ∈ Rd denotes the collection of system parameters and
u ∈ Rs denotes the input. h is called the observation function. From a
classical systems perspective, h might be referred to as the output of the
system, especially when considering input-output structure, but during
the modelling stage, it is helpful to be lucid about the distinction between
material outflow and observations.
2.4.2. Non-compartmental models
A model similar to a receptor-ligand binding model will be assumed for
the active uptake of artemisinins by red blood cells. Red blood cells
are treated as having a varying number of receptors based on whether
the cell is infected by malarial parasites, and the stage within the li-
fecycle of those parasites. Artemisinins are treated as ligands, which
form receptor-ligand complexes when bound to receptors in the red blood
cells. Compartmental models cannot conveniently be applied to model
receptor-ligand binding, because unless each complex compartment is
duplicated (for each species involved in the complex), the principle of
mass-balance is violated. Certain assumptions could generally be made
which can enable use of approximation by Michaelis-Menten kinetics, but
these assumptions are not valid in the particular receptor-ligand context
used here, and so this concept is not discussed.
The approach taken here is to relax the assumptions of “compart-
mental mass-balance”, which also means that simple model diagrams are
no longer sufficient to fully describe a model, because the concept of
“flow” is altered: a receptor and a ligand need to bind (i.e. a donation
needs to be made from 2 source compartments) in order for there to a be
a flow into the receptor-ligand complex compartment. Of course, mass-
balance equations still apply to such reactions but strictly compartmental
models require no merging or splitting of molecules. The other assump-
tions for compartmental models are carried forward to receptor-ligand
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models: flows are first-order and receptors and ligands are well-mixed
(equally accessible). It is also assumed that partial binding is not pos-
sible, and if the dissociation rate constant is non-zero, that binding does
not alter the ligand or receptor so each can again participate in a future
binding reaction.
Denoting the molar concentration of receptors by [R], the molar con-
centration of ligands by [L], the molar concentration of receptor-ligand
complex by [RL], the association rate constant by kon and the dissoci-
ation rate constant by koff, the equations describing the system are given
by the law of mass action:
d
dt [R] = −kon[R][L] + koff[RL],
d
dt [L] = −kon[R][L] + koff[RL],
d
dt [RL] = kon[R][L]− koff[RL].
It can therefore be seen that [R] + [RL] and [L] + [RL] are conserved
(constant) quantities.
Generally if such models are discussed on their own, they are depicted
similar to Figure 2.2. However, in this work, they will be incorporated
into a more complicated model that would otherwise be compartmental,
so the receptors will be shown as disconnected from the ligand and com-
plex compartments, and molecular quantities will be shown instead of
molar concentrations, as in Figure 2.3. It is noted that this does not
show all required details, but is felt to be clearer than diagrams where
such details are attempted to be shown, especially where the same re-
ceptor pool can bind to ligands from multiple different compartments.
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[R] [L] [RL]+
kon
koff
N Figure 2.2: Diagram representing receptor-ligand bind-
ing and associated rate constants
R
L RL
kon(t)
koff(t)
N Figure 2.3: Diagram representing receptor-ligand bind-
ing and associated non-linear rate flow rates
when used as a component in an otherwise
compartmental model
The general form of system model equations that will be considered
here is: 
q′(t) = f(q,p,u, t)
q(0) = q0(p)
y(t) = h(q,p, t),
(2.2)
(t ∈ T) which is very similar to (2.1) except that the compartmental
structure of f is no longer assumed (though the positivity constraint
still applies).
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2.5. Structural identifiability
2.5.1. Overview and importance
Once a structural model has been designed, it will very often have a
number of unknown parameters that might be particular to a certain pa-
tient or population, rather than having a value derived from a universal
physical law. In order for a model to have maximal utility, it is necessary
to estimate those unknown parameters and to specify the degree of cer-
tainty to which those estimates are valid. It may be the case that multiple
parameter sets have indistinguishable input/output (stimulus/response)
behaviour. In such cases, model utility may be limited since any inform-
ation extrapolated from the model may have a wide range of equally
plausible values, without there necessarily being any way to filter those
values into a meaningful or manageable range.
Once a candidate model and its input-output behaviour have been
selected, it becomes possible to ask the theoretical question of whether
that observable input/output behaviour (together with any relevant prior
knowledge) is sufficient to determine the necessary information for a par-
ticular application of the model, even before considering the issue of data
error or sampling frequency. Indeed (except for in certain machine learn-
ing situations where the parameters themselves are not of interest), the
question should be asked before attempting to collect or analyse data,
and where possible, attempts should be made to answer it. This question
is known as the structural identifiability question.
It is possible that the input/output behaviour is not influenced by
some of the system parameters, or that the influence is only in combina-
tions that do not allow to distinguish the parameters’ effects separately,
and these are the cases when a model is not structurally identifiable.
Structural identifiability is considered under the ideal assumptions of
having both a “perfect model and perfect data”, and (unless the situation
is altered by use of a prior distribution) is a prerequisite for the related
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questions of numerical and practical identifiability, where these assump-
tions are relaxed (though only partially so in the case of numerical identi-
fiability). A “perfect model” means that the model and the system being
modelled are identical [57, p. 20], while “perfect data” involves having
data available over a continuum of times (or less paradoxically, arbitrar-
ily dense data), for any time period of interest, and with no observation
error [58]. Structural identifiability is therefore a property of a structural
model, where that structure is taken to include the controls and observ-
ables. It is independent of any specific datasets, data sampling schemes
or data quantification methods. It is generally of interest to know not
only whether a model is structurally identifiable or not, but which para-
meters are structurally identifiable or structurally unidentifiable, and to
know the complete functional form of other parameter sets that are indis-
tinguishable from the input/output behaviour of the model. Depending
on the structure of the model, it can sometimes be easier to solve the
structural identifiability problem, involving an algebraic analysis, while
for other models, the algebra may be too difficult even for computational
algebra systems to solve, and so answering the numerical and/or practical
identifiability questions may be easier in those situations, though these
cannot directly give the same level of information. However, to determ-
ine the structural unidentifiability of the system, one only needs to find
one generically indistinguishable alternative parameter set, rather than
finding all such indistinguishable parameter sets which most structural
identifiability methods unavoidably attempt to do. Note that the related
problem of structural distinguishability between two or more models is
not considered in this work.
If the result of the structural identifiability analysis is that important
parameters are not structurally identifiable, then it may be necessary
to modify the model structure (including the observable input-output
behaviour) and restart the modelling procedure with a modified model.
Such an analysis is therefore ideally conducted before doing any experi-
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ments to determine whether those experiments are capable of producing
meaningful results, and/or to gain insights on how to improve such ex-
periments, for example by suggesting to make observations of another
state variable or variables (or functions thereof). However, it may also
be possible to re-parameterise the model in such a way that it becomes at
least structurally locally identifiable. It is for this reason that structural
unidentifiability is also termed parameter redundancy by some authors
[59].
Once it has been established that a model is structurally identifiable,
numerical and practical identifiability analyses can suggest specific times
at which it might be optimal to collect data samples from the system
being modelled, and can also be used to give an indication of how many
samples it might be appropriate to collect, or might provide the informa-
tion that, while the model might be structurally identifiable, estimation
of the parameters from the data it is planned to collect will still not be
practically possible.
Only after conducting these analyses should one proceed to actu-
ally attempt to collect real data of interest, or to use already collected
data for parameter inference. Attempting to estimate parameters from
a model whose structural, numerical and practical identifiability has not
been considered is to invite significant and severe problems, to which a
researcher may sometimes remain unaware; at best, they would be unable
to obtain any parameter estimates at all. At worst, incorrect conclusions
could be reached, and with false confidence.
2.5.2. Definitions
There are a number of subtly incompatible definitions in the literature for
structural identifiability, and even more so when expanding to differently
named concepts of identifiability. These differences and incompatibilities
are often perhaps (though certainly not always) unintentional.
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Fix a parameterised system modelM(p) of the form (2.2), and denote
by p = (p1, . . . , pd) a parameter vector parameterising the model. Let
Ω ⊆ Rd denote the space of feasible parameter values. Inequality con-
straints should be incorporated into the feasible parameter space. Only
those parameters which are to be considered unknown should be part of
the model parameterisation p in this section. Any parameters which are
to be considered as known functions of other parameters should also be
eliminated from the parameterisation. If a particular value for a para-
meter is known, it can sometimes be helpful to use that particular value
during the structural identifiability analysis, though equally the converse
can also be true: that using a generic parameter value makes the analysis
easier, and it is therefore wise to try both generic and specific situations.
Any other prior beliefs about the parameters can be considered in a
practical identifiability analysis through a prior distribution, rather than
being considered at this stage.
Note that a model in the above form includes specified initial condi-
tions, possibly in terms of unknown parameters. Though this setup is
intended here, it is worth noting that other authors advocate different
approaches and use different terms to describe the setup here [60].
• Let U ⊆ Rs be the space of admissible inputs to the system.
If the system is uncontrolled then take U = {∅} (i.e. the only
admissible input is the empty function). It is common to simply
refer to an output equation instead of an input/output equation in
such circumstances, without needing to involve the empty function.
• Let Σˆ(p):U → F(T;Rm) denote the input/output map for the
model M(p). This is the map such that Σˆ(p)(u) = y where
y:T → Rm are the observations from the model M(p) when its
input is u. This map plays a key role in structural identifiability,
but it is not always straightforward to obtain an algebraic form of
the input/output map for models of interest. A “structural identi-
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fiability method” generally refers to a method for either generating
such (generic) algebraic input/output maps, or generating exhaust-
ive summaries, which generically capture all the same information
as the input/output map.
Here, F(T;Rm) denotes the space of functions defined on the time
domain T with co-domain Rm.
Definition 1 (Parameter indistinguishability). Parameters p and p are
said to be indistinguishable underM iff Σˆ(p) = Σˆ(p).
Definition 2 (Exhaustive (parameter) summary). A function Σ: Ω →
RdΣ is called an exhaustive summary (or a structural invariant vector
[61]) forM iff for almost all values of p ∈ Ω,
Σ(p) = Σ(p) ⇐⇒ Σˆ(p) = Σˆ(p).
dΣ is allowed to be infinite in this definition, so an exhaustive sum-
mary may consist of a countably infinite sequence (e.g. as is the case for
Taylor series coefficients — see subsection 2.5.5).
Note that Σˆ is trivially an exhaustive summary. Exhaustive sum-
maries generically capture all the information that is available from the
observable input/output behaviour of the system model. Identifiabil-
ity and structural identifiability are concerned with whether or not the
information from the observable input/output behaviour of the model
is sufficient to distinguish one parameter set from another, i.e. whether
there exist distinct (and possibly arbitrarily close) parameters p,p with
the same observable behaviour Σˆ(p) = Σˆ(p).
Formally:
Definition 3 (Identifiability of parameter combinations at fixed p). Fix
p ∈ Ω. With respect toM, a parameter combination c(p) is said to be:
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• globally identifiable at p iff
if p ∈ Ω and Σˆ(p) = Σˆ(p) then c(p) = c(p); (2.3)
• (at least) locally identifiable at p iff there exists a neighbourhood
N(p) ⊆ Ω of vectors around p such that
if p ∈ N(p) and Σˆ(p) = Σˆ(p) then c(p) = c(p); (2.4)
• unidentifiable at p otherwise.
Note that the qualifier “at least” is replaced with the qualifier “non-
uniquely” when it is known that the parameter is not also globally identi-
fiable. These qualifiers remove the ambiguity that would otherwise arise
when referring to an (unqualified) “locally identifiable” parameter com-
bination.
In practice, one might assess the number of solutions to Σˆ(p) = Σˆ(p)
as follows. Write Sc(Σ, c(p)) to denote the set of all c(p) values within
such solutions, i.e.
Sc(Σ,p) :=
{
c(p): Σˆ(p) = Σˆ(p) for some p ∈ Ω
}
.
The condition of the parameter combination c being globally identifiable
(2.3) is equivalent to Sc(Σ,p) being a singleton set. If the cardinality of
the set Sc(Σ,p) is finite but distinct from (i.e. greater than) one, then
clearly c(p) is non-uniquely locally identifiable. It is common to take
c to be c(p) = pi (a scalar), to determine the identifiability of the i-
th component parameter of p, where the abbreviated notation Si will
be used here for the corresponding Sc. If Si(Σ,p) contains a closed
interval containing pi then clearly the model is unidentifiable at pi. With
more assumptions on the exhaustive summary and/or parameter space,
stronger statements can be made.
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If it is intended to only use a model with a single fixed input, then
it is better to move that input into the model equations directly and to
consider the model as an uncontrolled system. This is because, as can be
seen from the definition, structural identifiability uses information from
all permissible inputs, not a single fixed input. Some authors refer to
the concept of a “persistently exciting input” in an attempt to simplify
matters as they then need to consider only one input.
Now suppose that p is not fixed. The above definitions become their
structural counterparts when the conditions are required to hold for al-
most every p ∈ Ω:
Definition 4 (Structural identifiability of parameter combinations). A
parameter combination c(p) of p is said to be
• structurally globally identifiable (SGI) iff for almost every p ∈ Ω,
if p ∈ Ω and Σˆ(p) = Σˆ(p) then c(p) = c(p); (2.5)
• (at least) structurally locally identifiable (SLI) iff for almost every
p ∈ Ω, there exists a neighbourhood N(p) ⊆ Ω of vectors around
p such that
if p ∈ N(p) and Σˆ(p) = Σˆ(p) then c(p) = c(p); (2.6)
• structurally unidentifiable (SUI) otherwise.
Definition 5 (Identifiability and structural identifiability of models).
The identifiability status of the whole model at p is defined to be the
identifiability status of the identity parameter combination (c = identity
in Definition 3) at p.
Similarly, the structural identifiability status of the whole model is
defined to be the structural identifiability status of the identity parameter
combination in Definition 4.
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Equivalently, this can be expressed in terms of the identifiability of
the component parameters as follows (phrased only for structural iden-
tifiability for brevity):
• If all the component parameters in the model are structurally glob-
ally identifiable then the model itself is said to be structurally glob-
ally identifiable;
• The model is (at least) structurally locally identifiable iff all com-
ponent parameters of p are (at least) structurally locally identifi-
able;
• The model is structurally unidentifiable iff any of the component
parameters of p are structurally unidentifiable.
(Some authors prefer the term partially structurally identifiable iff
some but not all of the component parameters of p are structurally
unidentifiable.)
A model is therefore structurally globally (locally) identifiable iff there
exists a null set E with Σˆ (locally) injective when restricted to Ω \ E.
By the definition of exhaustive summaries, the input/output map in the
definitions of identifiability and structural identifiability can be replaced
with any exhaustive summary for the model. Most structural identifi-
ability methods work by producing a simpler exhaustive summary than
the original input/output map, upon which simpler methods (such as the
direct test method) can often be used to determine the generic injectivity
and thus structural identifiability.
Instead of solving Σ(p) = Σ(p) for p, it may sometimes be algebra-
ically simpler to solve
φ = Σ(p) for p when φ is in the range of Σ. (2.7)
This alternative formulation is just another way of checking the injectiv-
ity of the exhaustive summary, and so the number of generic solutions
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for c(p) still determines the structural identifiability of c(p).
Note that structural identifiability depends on each of the feasible
parameter space (and the a priori information incorporated into it), the
system model structure, the observations, the initial conditions, and the
admissible inputs.
2.5.3. Example to illustrate definitions
It will of course aid the reader to see examples of how the above defini-
tions work in practice. This subsection will illustrate those definitions in
the context of the well-known [54] two-compartment model depicted in
Figure 2.4.
1 2
y = αq2
bu(t)
k2,1
ke,1 ke,2
N Figure 2.4: Two compartment model used to illustrate
structural identifiability concepts and for
testing SMC sampler
This model is described by the following equations:

q′1(t) = bu(t)− (ke,1 + k2,1)q1(t)
q′2(t) = k2,1q1(t)− ke,2q2(t)
q1(0) = 0
q2(0) = 0
y(t) = αq2(t)
(2.8)
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for t ∈ T := R+.
Write p = (α, b, k2,1, ke,1, ke,2) so the input/output equation is given
by :
Σˆ(p) =
t 7→ αbk2,1 e−ke,2t − e−(k2,1+ke,1)t
k2,1 + ke,1 − ke,2
⊗ u, (2.9)
where ⊗ is the convolution operator.
The Laplace transform of the above expression is
s 7→ αbk2,1 1(s+ k2,1 + ke,1)(s+ ke,2)u(s), (2.10)
and so the Laplace transfer function is
s 7→ αbk2,1 1(s+ k2,1 + ke,1)(s+ ke,2) . (2.11)
Noting that there is never any pole-zero cancellation, the coefficients of
the Laplace transfer function (i.e. with the denominator expanded) are
αbk2,1, 1, k2,1 + ke,1 + ke,2, (k2,1 + ke,1)ke,2. (2.12)
Indistinguishability of the parameters under the input/output equation is
equivalent to indistinguishability of the coefficients of the Laplace trans-
fer function, within the meaning of Definition 1. Hence, the coefficients
form an exhaustive parameter summary for the model according to Defin-
ition 2. Call the coefficients Σ(p) and write p = (α, b, k2,1, ke,1, ke,2).
From the exhaustive parameter summary, note that if r > 0 and
p = (αr, b
r
, k2,1, ke,1, ke,2) then Σ(p) = Σ(p). As ∀ N(p), ∃ r >
0 such that (αr, b
r
, k2,1, ke,1, ke,2) ∈ N(p), this means (through Defini-
tion 4) that component parameters α and b are unidentifiable at any
p, and so in the more generic sense of structural identifiability, are also
structurally unidentifiable.
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Now note that
Σ(p) = Σ(p) =⇒ ke,1 = r and either
αb = αb k2,1
k2,1+ke,1−r , k2,1 = k2,1 + ke,1 − r, ke,2 = ke,2 or
αb = αb k2,1
ke,2−r , k2,1 = ke,2 − r, ke,2 = k2,1 + ke,1
for some r > 0. In particular, if Ω = (0,∞)5,
Sα = Sb = Sk2,1 = Ske,1 = (0,∞)
Ske,2 =
{
ke,2, k2,1 + ke,1
}
so the only component parameter of the model that is identifiable is
ke,2, which is locally identifiable at p (non-uniquely unless ke,2 = k2,1 +
ke,1) and is non-uniquely structurally locally identifiable. The remaining
parameters are (structurally) unidentifiable.
If instead ke,1 = 0 is known, then the indistinguishability conditions
reduce to

αb = αb, k2,1 = k2,1, ke,2 = ke,2 or
αb = αbk2,1
ke,2 , k2,1 = ke,2, ke,2 = k2,1,
(2.13)
and so
Sα = Sb = (0,∞)
Sαb =
αb, αbk2,1ke,2

Sk2,1 =
{
k2,1, ke,2
}
Ske,2 =
{
ke,2, k2,1
}
.
So, consider in turn the parameter combinations c(p) = αb, c(p) = k2,1,
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and c(p) = ke,2. If k2,1 = ke,2 then each of these parameter combinations
are globally identifiable at p, else they are only non-uniquely locally iden-
tifiable at p. Considering now the structural sense, where almost every
parameter has to be considered rather than a specific p, all the above
parameter combinations are non-uniquely structurally locally identifi-
able.
The model (with or without the assumption that ke,1 = 0) is struc-
turally unidentifiable (Definition 5) because the component parameters
α and b are structurally unidentifiable. Properly, in order to consider the
model (with the assumption that ke,1 = 0) to be identifiable, the model
ought first to be re-parameterised so that its state equations involve α
and b only through the product αb rather than through α and b separ-
ately, but this re-parameterisation step is not of interest in this thesis:
here it is enough to say that some parameters are considered to be com-
bined, and under this assumption, to treat the model as non-uniquely
structurally locally identifiable.
2.5.4. Abridged summary of available methods
There are a number of techniques available for determining the structural
identifiability of linear systems. The Laplace transform approach was
already introduced by way of the example in the previous subsection.
This, and other approaches, were discussed in more detail in Hall [1], and
are not repeated here. Techniques that are applicable to the more general
case of non-linear systems (and thus also to linear systems) are of interest
in this work. Such techniques include differential algebra approaches [62,
63, 64, 65], the similarity transformation approach (for compartmental
models) [66], the Taylor series approach [67] (discussed in more detail
in the next section), and local methods such as the Pohjanpalo rank
test [68], the Exact Arithmetic Rank (EAR) approach [69]. Many of
these approaches have been tried by the author but only the Taylor
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series approach is discussed in this work as it is the simplest of the few
approaches that were tractable for the models presented herein.
2.5.5. Taylor series coefficient approach
The Taylor series coefficients technique for structural identifiability can
be used for both linear and non-linear systems. It is relatively easy to cal-
culate the Taylor series coefficients for most models, though using these
coefficients to solve the structural identifiability problem can sometimes
prove to be computationally intractable even when other methods are
tractable.
Clearly, for given t∗,u,p,p, the following implication holds:
(
∀ t,y(t,u,p) = y(t,u,p)
)
=⇒
for all k ∈ N0 s.t. y(k) is defined,y(k)(t∗,u,p) = y(k)(t∗,u,p).
(2.14)
If y is analytic at t∗ then the reverse implication is also true. There-
fore, if y is analytic at t∗, the collection of Taylor series coefficients
(y(k)(t∗,u,p))k form an exhaustive summary.
If t∗ = 0 then the corresponding Taylor series coefficients of a model
in the form (2.2) can (in principle) be determined algebraically in terms
of the (symbolic) parameters and the initial value of the input functions.
If y is not analytic at 0 then the Taylor series coefficients can be
used to give a sufficient but not necessary method for determining struc-
tural identifiability [67, p. 23]: generic injectivity of the Taylor series
coefficients are sufficient but not necessary for structural identifiability.
Of course the Taylor series coefficients are in general an infinite series
which would not be practical to work with, but injectivity when restricted
to any n components implies injectivity for the whole series. Therefore,
truncating the Taylor series coefficients again gives a sufficient but not
generally necessary method for determining structural identifiability.
In certain settings, it can be shown that truncation to a certain num-
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ber of coefficients does again give a necessary and sufficient criterion.
2.5.6. Non-structural identifiability
Although structural identifiability is a necessary prerequisite to conduct
well-posed parameter inference on a model, it is not sufficient. It is also
often the case that the structural model is too complicated or cannot be
expressed in one of the required algebraic forms in order to conduct a
complete structural identifiability analysis. Clearly in these situations,
some evaluation of the identifiability of the model would be useful.
There are methods known as numerical identifiability and practical
(aka data-based [70]) identifiability methods that can be applied to a
wider class of models, though they are only able to produce local out-
comes. Instead of an algebraic or structural analysis of the model equa-
tions, a numerical or practical identifiability analysis uses numerical
methods to analyse the model, at specific numerical instances or collec-
tions of parameter values. There is no known agreed distinction between
the terms “numerical identifiability” and “practical identifiability”, but
the following convention will be used here: numerical identifiability will
be used to refer to identifiability using arbitrarily dense and noise-free
data generated from simulating the model under study, while practical
identifiability will refer to the situation where the data are not arbitrarily
dense, and/or not noise-free, and/or not simulated data. When simulated
data are used, the recovered parameters can be compared against the ori-
ginal parameter values that were used to generate the simulated data. It
is generally a good idea to conduct both numerical and practical identi-
fiability analyses: the numerical analysis with dense noise-free data and
the practical analysis with data sampling times and signal to noise ratio
corresponding to what one expects to see from a real data set, as well as
later with an actual real data set. Of course, if practical identifiability
is confirmed for a number of distinct parameter sets and model inputs,
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then it may not be necessary to consider numerical identifiability as well,
but a failure of practical identifiability may be caused by a failure of
numerical identifiability rather than the data simply being too sparse or
too noisy.
These types of analysis can provide insight to the kind of identifi-
ability problems in the sense of Definition 3, but not in the structural
sense of Definition 4, because the “almost everywhere” condition within
the definition of structural identifiability cannot be carried over to the
numeric case (specific instances of parameters always lie within a set
of zero measure). However, numerical and practical identifiability have
to be considered with respect to fixed inputs, and cannot be applied to
all inputs as is required by Definition 3, unless the set of inputs is a
singletonr finite set (though a persistently exciting input may be of use
here if available). Numerical and practical identifiability will together be
referred to as “non-structural identifiability” here. Usefully, numerical
and practical identifiability can often allow recovery of functional equa-
tions along which the likelihood stays constant [71], and it may then be
possible to use those functional equations to test the identifiability of the
model in a structural sense. As mentioned previously, it is much easier to
see if two given generic parameter sets are indistinguishable than to find
all indistinguishable parameter sets, and these identifiability methods can
help construct candidate parameter sets to test for indistinguishability.
For systems that are structurally globally identifiable, a failure of nu-
merical or practical identifiability will be due to limitations on the data
and/or the relationship between the data and the model, not the struc-
ture of the model itself. For systems that are not known to be structurally
globally identifiable, a failure of numerical or practical identifiability may
be due to lack of structural global identifiability in addition to or instead
of the above reasons.
Practical and numerical identifiability generally involve studying the
shape of the likelihood surface. Raue et al. [71] defines these kinds of iden-
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tifiability in relation to a parameter in terms of the size of a likelihood-
based confidence interval for that parameter: the confidence interval for
a numerically unidentifiable parameter (in log space) is the whole of R,
and extends to infinity in one direction for a practically unidentifiable
parameter.
One widely used approach for considering numerical or practical iden-
tifiability is the profile likelihood approach [71]. In case a Bayesian ana-
lysis is conducted, this can be replaced with a “profile posterior”. This
approach can be computationally costly, since it involves solving high-
dimensional optimisation problems on a fine mesh of points, but can be
parallelised and the resultant information is easy to interpret. Unfortu-
nately, it is difficult to reuse information from solving one optimisation
problem when solving an adjacent problem (where one of the parameters
has changed by a small value). Of course, in this case, another mode
of the likelihood may become dominant. A potentially more efficient
method for calculating profile likelihoods is proposed later in Section 3.2.
Practical identifiability problems, in the context of solving an op-
timisation problem, include the case that no solutions are found by the
optimiser, or where other solutions are returned by the optimiser in ad-
dition to or instead of any global optima. In the context of posterior
distributions, practical identifiability problems may occur where the pos-
terior has two or more modes that are not sufficiently separated to be
distinguished. In a practical identifiability analysis, the data sampling
frequency can be studied too.
Clearly, it may be useful to determine the practical identifiability
of a model in addition to other forms of identifiability. Therefore, it
is suggested to determine the structural identifiability of a model, or if
not possible then the numerical identifiability, followed by the practical
identifiability using synthetic data of a similar nature to that seen in real
data.
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2.6. Existing models for ARS
Many existing pharmacokinetic studies for artemisinins have been con-
ducted over the last couple of decades, and have successfully provided
some insights into the absorption, elimination and/or multiple dosing
behaviour of these drugs, and the covariates that influence these, includ-
ing the author’s own attempts in Hall [1] and Hall et al. [2]. Some studies
have restricted their interest to either healthy subjects, uncomplicated
malaria, or severe malaria, and either children, adults or pregnant wo-
men, while others have been designed specifically to consider the differ-
ences between some of these groups. Each study focusses on a specific
artemisinin derivative or derivatives, and a specific route or routes of
administration, either alone or in combination with other antimalarial
agents.
As mentioned in section 2.4, mechanistic models have the most utility.
Of the existing models that used mechanistic approaches, some have
been used to analyse the effects of differing dosing regimens in different
contexts, including cases where the malaria has developed resistance to
this class of drugs. They range from being very simple, e.g. with linear
absorption and exponential elimination as in Saralamba et al. [37], to
being quite complicated, e.g. involving 9 compartments as in Gordi et al.
[72], and of various complexities in between, e.g. 4 compartments as in
Tan et al. [73].
A goal of this work was to develop a model incorporating the parasite
lifecycle and stage-specific effects of the artemisinins. There are a few
existing models of parasite lifecycle, either alone or as part of larger
pharmacokinetic and pharmacodynamic models.
One such model is from Gravenor et al. [74], which splits the lifecycle
into a variable number of compartments of equal duration, each poten-
tially with their own death rates, but these death rates do not relate to
any pharmacokinetic data. The model allows for changes in the degree
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of synchronicity as the length of the parasite lifecycle is not fixed, but is
described by a gamma distribution with a mean of 48 hours and a stand-
ard deviation inversely proportional to the square root of the number of
compartments used.
A slightly similar model is Svensson et al. [47] which fixes the number
of age classes at 4, though this does not include stage-specific effects
(but could be adapted to do so, and indeed the authors note the same).
In order to account for parasite kill continuing beyond the decline of
artemisinin plasma concentrations, the model uses a intermediary pool of
damaged parasites still in general circulation, which are later removed by
the spleen in a first-order process. Rate of parasite damage was described
by first-order but time-varying dynamics, with the rate depending on the
time above a minimum inhibitory concentration.
The only known model incorporating stage-specific effects is from
Saralamba et al. [37]. The pharmacokinetic aspect of the model is
non-mechanistic with linear absorption and exponential elimination with
a single exponential term, which was well suited for their data-fitting
application but cannot be used to experiment with different dosing
strategies. The model makes many useful simplifying assumptions to
aid in their data-fitting application, but which are less suitable for a
predictive model. The model advances in discrete-time, assumes a nor-
mal age distribution of parasites and also assumes that all doses have
identical pharmacokinetic profiles. While this model showed excellent
performance despite its relative simplicity, for some patients there were
clearly systematic deviations from the model, which might be capable of
being explained by a more advanced model.
Most pharmacometric studies of artemisinin have shown that there
are vastly different volumes of distribution of artemisinin drugs between
healthy and infected persons, and the same is true even considering just
infected persons. The author speculates that this could possibly be due
to the take up in infected cells, and no model is currently known to exist
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with the capability to explore this possibility.
It is submitted there is a need for a new model where the pharma-
cokinetics and pharmacodynamics are both captured in detail, including
the interaction between the two, and one aim of this work is to develop
such a continuous-time model of the stage-specific effects of ARS and
DHA. The model previously published by the author [1, 2] was always
intended as a building block towards such a more complete model, and
will be revisited in subsection 2.6.1.
As has also been noted by Simpson et al. [75], few existing stud-
ies formally estimated pharmacokinetic or pharmacodynamic parameters
within a rigorous (preferably Bayesian) statistical framework using indi-
vidual patient data. The author agrees that a model’s behaviour with
respect to its parameters should be fully explored, and the sensitivity of
the model to its parameters be determined, including whether the para-
meters are estimable with sufficient precision. Indeed, this latter point is
related to the concepts of structural and practical identifiability, which
were important issues highlighted by the author in Hall [1] and Hall et al.
[2], yet those (still) appear to be the only models applied to artemisinins
that have been assessed for structural identifiability to date. One poten-
tial problem with developing a new complete model as desired above is
that it is likely to present unique mathematical and statistical challenges
due to its complexity, and existing structural identifiability techniques
may struggle in analysing such a model.
Finally, as noted above, Simpson et al. [75] expressed a preference
for conducting model fitting via a Bayesian analysis, another preference
shared by the author, despite conducting a non-Bayesian analysis in Hall
[1] and Hall et al. [2].
Therefore, the issues of structural and practical identifiability and
Bayesian analyses are explored in this work.
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2.6.1. Four compartment pharmacokinetic model
This section presents the model used by author previously in Hall et al.
[2], which was in turn based on one of the models presented in Hall [1].
Further analysis of this model is presented in section 4.1. This model is
also used as a base model for the novel model introduced in section 4.2.
2.6.1.1. Model structure
A relatively simple coupled mechanistic model was developed for the
pharmacokinetics of orally-administered ARS and its principle metabol-
ite DHA, for situations where blood plasma concentrations of both are
observed, and is depicted in Figure 2.5. It consists of four linked com-
partments, with the parent drug and its metabolite each represented
by two compartments: an absorption (gut) compartment and a circu-
lation/plasma compartment. The absorption compartments account for
the delay in the drug and metabolite reaching the circulation (and site
of measurement) due to the oral route of administration.
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1 3
2 4
bDδ(t)
y2(t) = α2q4(t)y1(t) = α1q2(t)
k21
k31
k43
k42
ke2
ke3
ke4
Artesunate
(ARS)
Dihydroartemisinin
(DHA)
Absorption:
Circulation:
N Figure 2.5: System diagram of the four compartment
model for ARS (left part) and DHA (right
part). Upper compartments represent
the absorption compartments (unobserved).
Lower compartments are the circulation
compartments (observed).
The administered oral dose of ARS is considered as a bolus (im-
pulsive) input into its absorption compartment (1 in the diagram). To
account for bioavailability, a fraction b of the administered dose D is
assumed to reach the systemic circulation. The dose D is prescribed in
proportion to the body weight of the patient, and so taken in units of
nmol per kg.
Once in the system, ARS is either irreversibly metabolised into DHA
(compartment 3) prior to reaching the circulation (compartment 4), or is
absorbed into the circulation (compartment 2) and subsequently meta-
bolised (compartment 4 again). Elimination can occur from any com-
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partment except the input compartment (compartment 1), and can be
caused by either excretion from the body or further metabolism into
inactive metabolites which are not of interest.
Observations are made of the drug concentrations in the circulation
compartments, with observation gains α1 for ARS (y1) and α2 for DHA
(y2). These parameters incorporate the volumes of distribution of the
respective drugs. As is standard for the purposes of assessing the iden-
tifiability of the structural model, “ideal observation” assumptions are
made, namely that observations are available continually over the entire
infinite time horizon, and further are available without error. These two
assumptions are relaxed later when dealing with the problem of para-
meter estimation from data.
Note that because metabolism of ARS into DHA takes place in the
liver as well as in esterases, metabolism can occur before presentation in
the observed circulation compartments. Indeed, in concentration–time
profiles of malaria patients (e.g. those analysed in this work), large quant-
ities of DHA are observed in the blood plasma prior to those of ARS,
which cannot be attributed solely to being artefacts of differing obser-
vation gains (or otherwise to quantification limits). Hence, the presence
of compartment 3 is crucial to capture the metabolism-before-absorption
route that ARS can take.
The differential equation characterisation of the model is given, for
t ∈ [0,∞) describing the time in hours since drug administration, by
(2.15)

q′(t) = Aq(t) + Bu(t)
q(0+) = q0
y(t) = Cq(t).
Here, q =
(
q1 q2 q3 q4
)T
represents the state vector of the system
model, where each qi denotes the quantity of the respective drug in com-
partment i, u(t) =
(
Dδ(t) 0 0 0
)T
denotes the model input and
q0 =
(
0 0 0 0
)T
the initial condition, y denotes the vector-valued
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observation function, and the model matrices are
A =

− (k21 + k31) 0 0 0
k21 − (k42 + ke2) 0 0
k31 0 − (k43 + ke3) 0
0 k42 k43 −ke4

, (2.16a)
B =

b
0
0
0

, C =
0 α1 0 0
0 0 0 α2
 . (2.16b)
Note that there are different ways to parameterise u, q0 and B. The
parameterisation used here has been chosen as it more clearly corresponds
to the mechanistic concepts.
As mentioned previously, due to the difference in the molecular
weights of the parent drug and the metabolite, the qi are considered
in units of molar mass, per kilogram of patient body weight (nmol/kg).
Observations, which are concentrations, are assumed to be in units of
nmol/l. The observation gains α1 and α2 therefore have units of kg/l, but
the volumes of distribution are generally assumed to scale approximately
linearly with patient body weight, hence the reason that the dosing is
calculated in those terms. (However, there is some debate about whether
or not allometric scaling might be more appropriate.)
All flows (absorption, metabolism and elimination) are assumed to
be first-order and linear, with rate constants kij (denoting the flow rate
constant to compartment i from compartment j, or to the environment
when i = e) time-invariant and specified in units of per hour (which are
standard units for artemisinin drugs). Note that conversion into inactive
unmeasured metabolites and excretion from the body are considered as
flows to the environment with respect to the system model.
The system of equations (2.15), with u(t) and q0 as described above,
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can easily be solved analytically to yield:
(2.17)q(t) = bDeAt , y(t) = Cq(t) .
The solution for the state variables is thus
(2.18)q1(t) = bDe−(k21+k31)t
q2(t) =
bDk21
(
e−(k42+ke2)t − e−(k21+k31)t
)
k21 + k31 − k42 − ke2
q3(t) =
bDk31
(
e−(k43+ke3)t − e−(k21+k31)t
)
k21 + k31 − k43 − ke3
q4(t) = bD
e−(k21+k31)t
k221k42 + k31k43(k31 − k42 − ke2) + k21(k31(k42 + k43)− k42(k43 + ke3))
(k21 + k31 − k42 − ke2)(k21 + k31 − k43 − ke3)(k21 + k31 − ke4)
− e
−(k42+ke2)tk21k42
(k21 + k31 − k42 − ke2)(k42 + ke2 − ke4)
− e
−(k43+ke3)tk31k43
(k21 + k31 − k43 − ke3)(k43 + ke3 − ke4)
+ e
−ke4t(k31k43(k42 + ke2 − ke4) + k21k42(k43 + ke3 − ke4))
(k21 + k31 − ke4)(k42 + ke2 − ke4)(k43 + ke3 − ke4)
 .
These equations are already seen to be somewhat unwieldy despite
the relative simplicity of the system model.
2.6.1.2. Model analysis
This model was analysed in Hall [1]. This analysis included a struc-
tural identifiability analysis using the Laplace transform method [54]
and highlighted problems with the Taylor series method [67] and similar-
ity transformation method [53]. The model was found to be structurally
unidentifiable, and so three constraints were identified that together were
sufficient to make the model structurally globally identifiable.
This model was also analysed further in Hall et al. [2]. These further
results include use of a slightly different form of those constraints, and use
of a more systematic approach of testing combinations of the constraints.
Some of this as well as a further improved analysis, including statistical
analysis, of this model is presented in this thesis in section 4.1.
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2.7. Statistical methods, inference and
quantification of results
2.7.1. Bayesian vs. non-Bayesian frameworks
In both Bayesian and classical statistical frameworks, it is normal to have
a likelihood function quantifying the support that the given data have
for arbitrary model parameters. In the classical framework, a point es-
timate of the parameters (the maximum likelihood estimate) is generally
sought. This can be problematic due to practical difficulties in confirm-
ing whether an estimate is genuinely the maximum likelihood estimate
(and indeed whether such an estimate is even unique) since global op-
timisation algorithms cannot identify the global maximum with perfect
certainty, and disallows identification or use of a secondary mode of the
likelihood function, although that secondary mode may sometimes be
more plausible or more compatible with other estimates (e.g. from dif-
ferent studies or from different subjects), and may only have a slightly
worse likelihood than the global maximum. In a Bayesian framework,
all the information known about the parameters a priori is encoded in
the form of a prior distribution, and this is combined with the likelihood,
which contains all the information the data tell us about the parameters,
to give a posterior distribution, which assigns a probability to each po-
tential parameter vector. Such probabilities quantify the degree of belief
that the parameter vector matches the data.
Many authors advocate use of Bayesian posterior distributions in
scientific applications (e.g. [75]). These contain much more informa-
tion, especially regarding uncertainty, than simply determining point es-
timates or confidence bands for the parameters and model predictions.
Correspondingly, Bayesian information is much more useful to a practi-
tioner, and allows a more thorough exploration of the relevant scenarios.
Bayesian methods also allow borrowing of information across subjects
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in mixed effects situations, which would not be so readily possible in a
classical framework. (Mixed effects models are a topic for future work
and are not discussed in this thesis.)
However, calculating a probability distribution instead of just a point
estimate involves much more computation and different assumptions.
One immediate difference is that instead of simply specifying a feasible
parameter region, it is necessary to quantify a priori how feasible each
particular parameter combination is, and this is not always straightfor-
ward. This is known as specifying a prior distribution on the parameters.
Priors can be informative or uninformative, depending on what inform-
ation is known a priori and how many assumptions one wants to make
at this stage. If information is known from other studies, then including
that information as a prior assumption essentially prevents confirma-
tion of that same information. Potential problems can arise when little
is known (or incorporated) in the prior distribution, for example if no
parameter may be a priori unbounded, as a proper prior is required to
integrate to a total probability of one. Additionally, priors are not invari-
ant under transformations and so, for example, a prior that may appear
to be uninformative may in fact be significantly discriminatory towards
a different parameterisation.
Priors also have an effect on identifiability: if a parameter is struc-
turally or practically unidentifiable but the corresponding prior has (for
example) a single point with maximal density, then that single point will
generally be identified, though this depends on the exact nature of the
practical unidentifiability. Indeed, many people impose certain priors
deliberately so that they get an identifiable model, but naturally this
should only be used to resolve practical identifiability concerns rather
than structural ones. It is also possible for a prior to render an otherwise
structurally identifiable model into an unidentifiable model, but this is
pathological and unlikely to occur in practice without a specific aim to
set up such a situation.
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Throughout this work, proper uniform priors with finite support are
used.
In quantifying the results from a Bayesian analysis, it is largely a
case of expressing or otherwise summarising the posterior distribution
and its marginals, but in a non-Bayesian analysis, it is common to have
to conduct further calculations under further (and possibly exaggerated)
assumptions, for example an asymptotic variance-covariance matrix (see
subsection 2.7.4).
2.7.2. Likelihood functions
Unlike for the structural identifiability analysis, the observations are now
assumed to be finite in number and collected at discrete times. Selection
of an error model and a predictive model determines the likelihood func-
tion. Only observation error is considered, as error resulting from model
misspecification is assumed to be dominated by observation error.
So, let yi denote the ith observation, and hi(θ) denote the corres-
ponding model prediction under parameters θ. Then,
i := r(yi, hi(θ)),
denotes the (modified) model residual under parameters θ for observation
i.
Due to the properties of the drug assays used (discussed in sec-
tion 2.3), it is assumed that the model residuals for drug concentrations
are normally distributed, with mean zero, and variance proportional to
the model predicted value. For simplicity, the same is assumed for para-
site observations. Note that this error model does not account for the
fact that the observed concentrations will always be positive, but is nev-
ertheless convenient to work with. For both the drug assays and the
model residuals, other distributional assumptions could be made, such
as the Laplace distribution (which instead of penalising a large squared
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difference from the mean, penalises a large absolute difference from the
mean, and so has a sharper peak, fatter tails and is more tolerant to
outliers) or Student’s t-distribution (which maintains a similar shape to
the normal distribution but again has fatter tails). These other distri-
butions are relatively easy to incorporate into a Bayesian analysis of
the kind conducted here, though no comparison of the effect of these
different distributions were made here: the normal distribution was used
throughout. The results section later discusses whether a different choice
of distribution might ultimately have been beneficial.
In symbols,
i ∼ N(0, (δihi(θ))2). (2.19)
The drug assays have a coefficient of variation reported at 15%, so δi =
0.15.
It is further assumed that the observation errors for observations at
different times are independent. (This assumption may not be realistic
but is felt to be a good starting point in the absence of any prior in-
formation to the contrary.) It is also assumed that there is no correla-
tion between observation errors of drug concentrations and parasitaemia.
Observation errors for ARS and DHA observations obtained at the same
time are assumed to be correlated with correlation parameter ρ unknown.
It is convenient to view the yi as forming a one-dimensional vector.
Write y for the data and h(θ) for their model predictions. The above
specification gives rise to the following log-likelihood function, defined up
to an additive arbitrary constant:
`
(
θ |y
)
= −12
log det V(θ) +
(
r(y,h(θ))
)T
V(θ)−1
(
r(y,h(θ))
)
︸ ︷︷ ︸
weighted residual sum of squares (WRSS)
 ,
(2.20)
where V(θ) is the weighting matrix with (i, i)-th element σ2i and (i, j)-
th element ρσiσj when ti = tj, i 6= j, and i, j are observations of drug
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concentrations, and 0 otherwise. Here, r(y,h(θ)) is the modified residual
according to the rules in the following section, which coincides with the
standard residual r(y,x) = y − x when neither argument is below the
applicable censoring thresholds.
2.7.3. Censoring
In both datasets used in this work, data of drug concentrations below the
limit of quantification are not reported with a numerical value but are
simply reported as being below the limit of quantification. These data
points are therefore said to be “left censored”; the values are below a
known threshold but it is not known how far below the threshold. There
are also some data points in the MORU_ARC3_PD dataset correspond-
ing to drug concentrations so low that no distinct peak could be identified
in the HPLC traces; these are reported as “no peak”. This is essentially
the same as detecting no drug in the sample, but the HPLC method does
not have perfect sensitivity so it would not be quite accurate to report
the drug concentration as 0. These data points are therefore also best
considered as left censored, but with a lower threshold than the limit of
quantification. Indeed, some assays report a limit of detection which is
the appropriate threshold in this situation.
Clearly, data points that are below the limit of quantification or below
the limit of detection still carry a significant amount of information, so
this information needs to be incorporated into the statistical analysis
rather than discarding such points. Nevertheless, these points must be
treated distinctly from other data points where values are reported.
In this work, left censored data points will be handled by treating
the model residual as zero where both the data point and the model
prediction lie below the unobserved threshold. Any model predictions
or data points below the threshold are treated as though they were at
the threshold. If a model prediction and corresponding data point are
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both left censored but with different thresholds then the point within
the larger threshold is treated as though it was half way between the two
thresholds.
2.7.4. Maximum likelihood estimation and uncer-
tainty quantification
In a non-Bayesian framework, standard numerical optimisation meth-
ods are generally used to find a minimiser θˆ of the negative of the log-
likelihood expression (hereafter referred to as the objective function), and
the minimiser is used as “the best” estimate of the parameters, though
the likelihood function is often multi-modal and it can be hard to ensure
that a global minimum is found. Indeed, in non-practically identifiable
situations, such a global minimum may not be unique and/or there may
be multiple local minima that exacerbate the problem of finding global
minima.
To attempt to quantify the uncertainty in the parameter estimates
in a non-Bayesian analysis, the asymptotic (for a large number of obser-
vations) distribution of the parameter estimates can be estimated [76].
The asymptotic distribution of the parameter estimate θˆ is approxim-
ately MVN(θ∗,C) where MVN denotes the multivariate normal family
of distributions, θ∗ is the “true” value of θ and the variance-covariance
matrix C is described next. Consider the linear approximation to the
dependence of the unweighted residuals on the parameters about the
estimate θˆ:
R(θˆ) = ∂
∂θT
(
y − h(θ)
) ∣∣∣
θ=θˆ
. (2.21)
The inverse of the Fisher information matrix at θˆ provides an estimate
C of the asymptotic variance-covariance matrix for θˆ,
C =
(
R(θˆ)TV(θˆ)−1R(θˆ)
)−1
. (2.22)
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The variance-covariance matrix C is easier to interpret by reporting
the diagonal elements of C together with the correlation matrix formed
by dividing the respective rows and columns by the square roots of these
diagonal elements. This information fully specifies C but is easier to
compare and contrast than C itself.
2.7.5. Goodness of fit statistics
Likelihood function values and WRSS values are not directly comparable
between subjects, due to each data set having a different variation to
begin with. Instead, the (weighted) coefficient of determination can be
used. Loosely speaking, this expresses the variation in the data explained
by the model as a ratio of the total variation present in the data, and is
defined as
R2 := 100
1−
(
r(y,h(θ))
)T
V(p)−1
(
r(y,h(θ))
)
(y − y)T V(p)−1 (y − y)
 %, (2.23)
where the elements of y are the average of the observed values for the
corresponding curve.
The idea is that a larger coefficient of determination should indicate
a better fit. However, a large value of this statistic does not necessarily
correspond to a high likelihood, which is in some ways problematic as
the objective is to maximise the likelihood not the coefficient of determ-
ination, but it does accord at least qualitatively with a visual analysis of
fits. (Note that the baseline model is simply a mean model, which is not
contained in the fitted model class, so the ANOVA interpretation of this
statistic does not apply.)
2.7.6. Monte Carlo methods
It is well-known that many common problems that need to be solved
in order to conduct a Bayesian analysis quickly become intractable to
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do directly as the dimension increases. This is known as the curse of
dimensionality. These common problems include sampling from a dis-
tribution, determining the normalising constant for a density, and/or
determining the maximal density regions of a distribution. Therefore,
high-dimensional problems require specially tailored analysis methods.
Most of these methods work by approximate simulation, which can in
principle operate to any desired degree of accuracy, and they are known
as Monte Carlo methods.
A simple but efficient class of such methods are Sequential Monte
Carlo (SMC) methods, used extensively here.
2.7.6.1. Sequential Monte Carlo (SMC)
Suppose pi is a (possibly high-dimensional) distribution of interest (such
as a posterior distribution), referred to hereafter as the target distribu-
tion. Instead of trying to work directly with this target distribution (due
to the reasons identified above), it is often helpful to sequentially estim-
ate some intermediaries pi0, . . . , piT−1, before finally arriving at the target
distribution piT = pi (where T is not necessarily fixed and may instead be
determined adaptively). In an SMC sampler, each distribution is approx-
imated by a collection of weighted particles (random samples). In the
application here, each particle is actually a parameter set from the para-
meter space of the model, and the weight represents (up to a constant
of proportionality) the plausibility of that parameter set in terms of de-
scribing the observed data under the relevant assumptions, which can be
compared relative to the weights of the other particles in the collection.
Particles that have a relatively low weight and so contribute little to the
approximation of the distribution may ultimately be discarded/replaced.
The idea is that successive distributions are ‘close’, so generating
samples from pin+1 is easier when samples from pin are already available.
An SMC sampler exploits this when propagating the weighted particles
from each distribution in the sequence to the next. Hence, a sample from
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pi is constructed sequentially. SMC samplers are applied in situations
where sampling from pi0 and then proceeding sequentially is much easier
than sampling directly from piT (despite there being potentially many
such intermediate distributions, i.e. with a large value of T ). The starting
distribution pi0 is chosen to be a distribution that is easy to sample from.
Although there are other occasions where SMC samplers are useful, the
above situation is the motivation behind using SMC in this work.
As SMC is a simulation method, it requires some tuning, diagnostics
and validation, has a high computational cost and only produces approx-
imate output. However, it is felt that each of these aspects are somewhat
simpler or more satisfactory with SMC than other methods, and it is a
proven and widely adopted and trusted method that can make use of
modern computing facilities (which tend to involve parallel computa-
tion).
The parameter space Θ for each distribution in the sequence will be
taken to be the same. This is not restrictive for the purposes here. It will
be assumed that pi admits a density with respect to Lebesgue measure,
as will always be the case for distributions used in this work, and making
this assumption now provides for notational simplicity. For complete
details on SMC in its original generality, see Del Moral et al. [77]. Only
sufficient details are given in this thesis for the purposes required herein.
When describing distributions used in Monte Carlo methods, it is
common to need to distinguish between the distributions themselves,
their density functions, and because the latter are normally known only
up to a constant of proportionality, kernels or intensities (unnormalised
densities) for the distribution with respect to a particular constant of
proportionality. Unnormalised densities may also be used where the nor-
malising constant is not relevant (e.g. due to being multiplied by terms
that are also unnormalised). In this work, for a distribution denoted by
pi, its density function will be denoted [pi] and an unnormalised density
for it will be denoted by JpiK. Hopefully this convention will aid the reader
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more than using different symbols for each of these functions would. The
constant of proportionality is not directly of interest here and no special
notation will be introduced for that.
In some applications, there will be a natural sequence of distributions
to consider, for example observations could be incorporated sequentially,
leading to a sequence of distributions referred to as a data tempered se-
quence. Such a sequence has the advantage that the intermediate distri-
butions are meaningful; the posterior likelihood can be updated “on-line”
and possibly in real-time as new observations arrive. However, in such a
sequence, the number of intermediate distributions is constrained by the
number of observations available and this may not be an ideal way to
reach the target distribution, especially where the analysis is conducted
“off-line”, i.e. where all the observations are already available.
Here, all observations are already available for incorporation simul-
taneously rather than sequentially, and so distribution tempering is used
to produce appropriate sequences of distributions. Use of such distribu-
tion tempering schemes within SMC has not been widely documented
but is becoming more popular [78, 79, 80]. The sequence of distributions
is taken as (pi0, . . . , pit, . . . , piT ) where each pit is defined by
JpitK = x 7→ (JpiK (x))φt , (2.24)
with 0 = φ0 < · · · < φT = 1 and pi is the target distribution of interest
(i.e. the posterior).
Naturally, for observations assumed to come from a single fixed model,
pi is taken to be the posterior distribution of the parameters given the
data, derived from Bayes’ theorem as the prior distribution ν times the
likelihood: JpiK = θ ∈ Θ 7→ JνK (θ)L(y1, . . . , yc;θ), (2.25)
where y1, . . . , yc denote the observations (and without loss of generality,
can be considered to be scalar-valued), and L denotes the likelihood
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function (which may also have irrelevant constant factors removed), so
the sequence of distributions used in the distribution tempering scheme
is {pit}t where
JpitK = θ ∈ Θ 7→ JνK (θ)L(y1, . . . , yc;θ)φt , (2.26)
ν is the prior distribution. Note that at the final iteration T , φT = 1 and
so [piT ] = pi, the target distribution as in (2.25).
With this method, it is necessary to be able to evaluate the likelihoods
L(y1, . . . , yc;θ) pointwise, but this is certainly not a problem in the ap-
plications here. However, it is worth noting that it will sometimes be
necessary to use an ODE solver to compute these likelihoods, which will
naturally slow down the computations to a significant, but non-crippling
extent. Crucially, it is also the case that the constants of proportionality
(i.e. those not depending on θ) of each intermediate distribution need
not be known a priori, but can (if of interest) be estimated by the SMC
sampler.
It is convenient to work with logarithms of the (unnormalised) density
functions of the distributions:
log JpitK = θ ∈ Θ 7→ constant + log JνK (θ) + φt logL(y1, . . . , yc;θ)︸ ︷︷ ︸
(`θ |y)
,
and in this situation, the constant additive term, not depending on θ,
incorporates the normalising constant and need not be known.
With the same assumptions as presented in (2.20),
`
(
θ |y
)
= −12
log det V(θ) + r(y,θ)TV(θ)−1r(y,θ)︸ ︷︷ ︸
weighted residual sum of squares (WRSS)
 , (2.27)
where r(y,θ) =
(
y − h(θ)
)
is the modified residual (modified since, if
censoring occurs, it may be cut-off at the limit of quantification). See
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again subsection 2.7.2 where other error distributions were discussed.
In practice, the speed of the SMC sampler is important, so where
simplifications can be made to the above equation, e.g. where V is known
to be a diagonal or block diagonal matrix, these optimisations are built
into the code and provide significant speed ups in those situations. This
is worth the extra maintenance effort of having to maintain multiple
different versions of the likelihood calculation code (i.e. in the diagonal,
block diagonal and dense matrix cases).
During the SMC runs, it often happens that all but a few particles
gain negligible weights; in other words, the particle system is degenerate.
A convenient indicator of the degree of degeneracy is the “survival dia-
gnostic”, or the number of effective particles Neff (often referred to as the
effective sample size, but this terminology is avoided here as it conflicts
with the separate notion of effective sample size used in Equation 2.30
later, and is also somewhat misleading; again discussed later) [81]. The
survival diagnostic is calculated as [82]:
Neff =
1∑N
i=1(w(i))2
,
where w(i) is the normalised weight of the ith particle. After every it-
eration of the SMC sampler, the survival diagnostic should be tested to
see if it is below a given threshold, and if so, to resample the particles:
the new particle system (usually with the same number of particles) con-
tains replicates of the previous particles in proportion to their weights,
with the weights all set to be equal in the new system. This effectively
means that particles with high weights will have lots of replicates in the
new system (with the new replicates able to be moved independently in
the next iteration), whereas particles with low weights will be omitted
completely. There are various resampling schemes available that satisfy
the above descriptive constraints, including stratified, multinomial and
residual resampling. These schemes are not discussed here, except to
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say that residual resampling will be used throughout, as it exhibits lower
conditional variance for all configurations of the weights [83]. It is pos-
sible for the SMC algorithm to recover from situations where the survival
diagnostic falls to a low level, although this may take several iterations.
Therefore, it is helpful to warn if the survival diagnostic becomes quite
low before resampling, especially if this occurs with t close to T . Note
that it is somewhat misleading to refer to the survival diagnostic as an
effective sample size, because immediately upon resampling, the weights
are reset to be equal and so the survival diagnostic is restored to the
number of particles N , even though many of the particles will not be
distinct.
As resampling introduces extra Monte Carlo error, it is not done un-
less necessary (i.e. the survival diagnostic is below a given threshold), and
all calculations should be done before resampling where possible, e.g. ad-
apting the proposal variance, or analysing the final particle distribution
from the last iteration of the sampler. However, this makes those calcu-
lations slightly harder as they must work with a set of weighted particles
rather than particles with uniform weights, as they would be following a
resampling step.
The matters of selecting the SMC parameters, and evaluating conver-
gence etc, will be discussed in the next subsection, subsubsection 2.7.6.2.
There are many different (but similar) versions of SMC algorithms.
Some differ in the order of the component steps per iteration (e.g. re-
weight, select/resample, mutate, advance iteration number). The follow-
ing algorithm describes the one used in this work and is very much like
the standard versions [77], but with the simplifying assumptions that
pit ≈ pit−1, and with the otherwise arbitrary backwards Markov kernel
chosen to be the time-reversed proposal kernel. This has allowed separ-
ation of the reweighting and mutation steps, whereas without the above
choices, the incremental weights will depend on both the previous and
new particle positions.
62
2. Background and literature review
Under the assumptions that the distributions pit are invariant under
their respective mutation kernels Kt — written in symbols as follows:
pit = pitKt and pit−1 ≈ pit, (2.28)
— the listing in Algorithm 1 summarises the version of the SMC al-
gorithm used in this work.
A framework in C++ called SMCTC [84] allows implementing such
algorithms relatively straightforwardly, and was used here. (Although
other frameworks were available, none were found to be as powerful or
easy to use, and a comparison of such frameworks is not a focus of this
work. Other frameworks became available during this work [85, 86, 87]
but arrived after the implementation in SMCTC was already underway
and so were not evaluated.)
As alluded to earlier, it is also worth mentioning that, in contrast to
standard MCMC methods, SMC samplers are relatively easy to par-
allelise. The particles can be easily divided into chunks and differ-
ent processors/machines can operate on different chunks simultaneously.
Most operations are on individual particles and are independent of other
particles, therefore these steps can readily be done in parallel. Of course,
information from different instances needs to be merged when analys-
ing variance, determining total weight, etc, but these steps happen a
lot less frequently than the particle mutation steps, and do not require
transmission of the entire particle collection, just aggregate information
computed in parallel. Work on parallel SMC samplers has begun (e.g.
[85]) but have considerably higher complexity than non-parallel variants.
As the SMC runs needed in this work were able to be completed in
practically acceptable time periods without requiring to take advantage
of parallel environments, parallelisation was not employed. However, it
may be necessary to employ parallel methods to complete the analysis of
the model presented in section 4.2.
63
2. Background and literature review
Algorithm 1 SMC algorithm for approximating piT with the assump-
tions (2.28)
1: Initialization:
2: Choose an appropriate number of particles N and either the se-
quence of intermediate distributions pi0, . . . , piT , or a proced-
ure for determining the same.
3: Step t = 0: Particles are initialised by sampling from the initial
distribution pi0. pi0 should be chosen so that this can either be
done directly or with standard importance sampling methods.
Write η0 for the corresponding importance distribution (often
η0 = pi0).
For each particle i, sample θ(i)t ∼ pi0 and set w(i)0 =Jpi0K(θ(i)t )Jη0K(θ(i)t ) to be the importance weight.
Normalise the particle weights.
4: Choose an appropriate initial proposal scale Σ1.
5: Iteration:
6: for t = 1, . . . , T do
7: Reweighting:
8: The weight of each particle i is incremented from its weight
in the previous iteration by multiplying by its unnor-
malised incremental weight, i.e:
w
(i)
t ← w(i)t−1ω(i)t
where the unnormalised incremental weight is
ω
(i)
t = JpitK (θ(i)t−1)/qpit−1y(θ(i)t−1).
9: Renormalise the weights if necessary.
10: Detect if there were any issues in the distance between pit−1
and pit (e.g. the ESS has fallen too far or the dχ2 is too
large), and warn appropriately.
11: Optionally, adapt proposal scales Σ˜t and/or distribution
sequence.
12: Resampling:
13: if the survival diagnostic has fallen below the resampling
threshold, then resample.
14: if the survival diagnostic has fallen below the warning
threshold, then warn appropriately.
15: Mutation:
16: For each particle i, sample θ(i)t ∼ Kt,Σ˜t(θ(i)t−1, ·).
17: Optionally, save the state of the particle system (and/or other
information obtained during the iteration) for later inspec-
tion.
18: end for
19: Output:
20: When the above has finished, the collection of weighted particles
(θ(i)T , w
(i)
T ), form an approximation of piT .
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2.7.6.2. Choice of SMC proposal
It should be clear that with SMC samplers, there is always a trade off
of number of particles, number of intermediate distributions and speed
(and memory requirements) of computation. More intermediate distribu-
tions means closer successive distributions, while more particles means
a potentially finer approximation of each distribution. The larger the
number of parameters to be sampled, the larger the number of particles
and number of iterations that should be selected, but there is no general
rule of thumb for selecting these “meta” parameters.
It is convenient to select K by means of a proposal kernel together
with an accept-reject step. Writing Q for the proposal and α for the
acceptance probability:
Kt,Σ˜t(x, ·) = A 7→
∫
A
Qt,Σ˜t(x,y)αt(x,y) dy +
(
1− cx,t,Σ˜t
)
δx(A)
where
cx,t,Σ˜t =
∫
Rd
Qt,Σ˜t(x, ·)αt(x, ·),
and
αt(x,y) = min
JpitK (y)Qt,Σ˜t(y,x)JpitK (x)Qt,Σ˜t(x,y) , 1

This is equivalent to drawing a proposal from Qt,Σ˜t(x, ·) and accept-
ing this proposed state (i.e. storing θ(i)t ← x) with probability αt(x,y),
otherwise leaving the state unchanged. Note that this satisfies the as-
sumption that Kt is pit-invariant.
For the purposes here, Qt,Σ˜t(x, ·) is chosen to be a Metropolis random
walk starting at x, with covariance matrix Σ˜t. This is a special case of
a Metropolis-Hastings random walk with a symmetrical proposal. The
symmetry allows for a simpler description of the mutation step as follows:
For each particle i, draw a sample from Qt,Σ˜t(0, ·) and add it to the
current state θ(i)t to give a proposed state x. The acceptance probability
then simplifies to JpitK (x)/JpitK (θ(i)t ).
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If the proposal variance is too small then, depending on the distri-
bution in question and how different it was to the previous distribution,
the acceptance rate will be high but the particles will move around the
space slowly, which might correspond to the particle cloud from the next
iteration not adequately representing that iteration’s target distribution.
Conversely, if the proposal variance is too large then, again depending on
the distributions in question, it is likely that the proposals will be in re-
gions of lower density and so the acceptance rate will be lower. Again this
might mean that the particle cloud is not a good representation of the
intermediate distribution. This therefore suggests that it is important to
select the proposal variance and monitor the acceptance rate carefully,
but fortunately SMC samplers are more robust than similar MCMC al-
gorithms, in that the whole probability distribution is estimated at each
iteration, and the next distribution in the sequence is not too dissimilar
from the previous. Indeed, some thought should be given to the selection
of the proposal variance, but generally increasing the number of inter-
mediate distributions will allay such issues, provided the acceptance rate
isn’t either extremely high or extremely low. When using distribution
tempering, and without adapting the proposals, it is usually observed
that the accept rate will decrease with every iteration, so adaptation of
the proposal variance is important in SMC settings.
Roberts and Rosenthal [88] found an optimal proposal in a certain
high-dimensional MCMC setting, which was:
Kt(x,x+ ·) = (1− β)N(0, (2.38)2Σt/d) + βN(0, (0.1)2Id/d),
where Σt denotes the empirical covariance matrix of the tth iteration,
and they found the optimal acceptance rate in such settings to be 0.234.
As this was an MCMC context rather than an SMC context, it required
t > d for it even to make sense, but the condition imposed was t > 2d
presumably for stability. β was taken to be 0.05 and this component (that
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does not depend on the covariance matrix) ensured that the algorithm
did not get stuck if the covariance matrix Σ became singular at any
point.
Although the context here is not the same, it still seems reasonable to
select a similar proposal and aim for a similar acceptance rate. Used here
is the following adaptation, which does not necessarily satisfy the dimin-
ishing adaptation condition or other assumptions that were necessary in
the MCMC context:
(1− β)N(0, ft(2.38)2Σ˜t/d) + βN(0, (0.1)2Id/d),
although if the covariance matrix was found to be singular, β was tem-
porarily increased to 1. The factor fn is another type of adaptation
introduced, with f1 = 1 and ft+1 = max(min(1 + (at− 0.234), 1.1), 0.9)ft
where at denotes the accept rate of iteration t. This is not dissimilar to
the scheme proposed by Roberts and Rosenthal [88], but here the dimin-
ishing adaptation condition is not required so the adjustment factor is
not itself scaled according to the iteration. Other approaches could of
course be adopted that use more information about the history of the
acceptance rate over previous iterations, which would better facilitate
reaching or remaining at the target acceptance rate, but is felt to be un-
necessary here, especially as the target acceptance rate is not known to
be optimal in this context. In any event, only a reasonable performance
is needed, not an “optimal” performance.
The proposal scale Σ˜t can be updated (based on the covariance Σt of
whole particle system) every K SMC iterations (say) for some K. As the
covariance of the particle system is relatively inexpensive to compute, it
is feasible to take K = 1, so that is done here.
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2.7.6.3. Choice of SMC tempering schedule
The tempering schedule is not adapted here, but a sensible scheme has
been proposed by Zhou et al. [78], who suggests aiming for a fixed reduc-
tion in the conditional ESS, a quantity also defined by him. Instead, a
fixed geometric-based tempering schedule is applied instead: φk =
(
k
T
)λ
with λ > 1 chosen so that pi1 is reasonably close to pi0, as the jump
between these two distributions in particular is substantially different to
that of any other adjacent distributions. This could be described as a
deterministic adaptation, but the term “adaptive” here is reserved for
dynamic adaptation cases.
While tuning the parameters, it may be helpful to run the SMC solver
only up to some iteration t < T (e.g. just for the first one or two itera-
tions or so), to check that things are working correctly and the distance
between the first two distributions is not too large.
2.7.6.4. Assessing convergence of SMC runs
Diagnostics for sample impoverishment are borrowed from Carpenter et
al. [89] (which was a particle filtering context). Somewhat confusingly,
these are also referred to as effective sample sizes. Although this is not a
particle filtering context, the same concept applies without modification.
If one is interested in the property
∫
g(θt) dL(xk|Dk), (2.29)
(for instance with g taken to give the marginal means of a parameter)
then, with M replicates of weighted particles (x(m,j)k , w
(m,j)
k ) (for m =
1, . . . ,M), the effective sample size of the property is
Mvk/
M∑
m=1
(
z
(m)
k − zk
)2
(2.30)
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where
z
(m)
k =
∑N
j=1w
(m,j)
k g(x
(m,j)
k ),
v
(m)
k =
∑N
j=1w
(m,j)
k g
2(x(m,j)k )− z2k
(2.31)
and zk, vk are the average values of the M replicates of zk, vk respectively.
2.7.6.5. Chi-squared distance between distributions
Knowledge of the “distance” between distributions is useful to check that
distributions of the SMC sampler corresponding to successive iterations
are sufficiently close for the SMC to perform effectively. It can also be
used to give some insight into the identifiability of the problem, and this
aspect is discussed in the next subsection.
The chi-squared distance between two distributions φ and µ is defined
as [90]:
dχ2(φ, µ) = Varµ(
[
φ(X)
]
/
[
µ(X)
]
)
= Eµ(([φ] (X)/[µ] (X))2)− (Eµ([φ] (X)/[µ] (X)))2
=
∫
([φ] /[µ])2 [µ]− (∫ [φ] /[µ] [µ])2 = (∫ [φ]2 /[µ])− 1
(2.32)
Of course, sufficient knowledge of either or both of φ and µ is required
to calculate this quantity directly, and is often not available or not feas-
ible to obtain since the curse of dimensionality arises again. Therefore,
Monte Carlo approximations of χ2 distances are calculated in this work,
which involve little extra effort when a Monte Carlo approximation of
the distribution φ is already available. The integral is replaced with an
importance sampling integral, and the normalising constants of φ and µ
are also estimated with importance sampling integrals. Obviously mul-
tiple replicates should be obtained and averaged but a single replicate can
still be informative. However, in this setup, if φ is not a good importance
base distribution for µ, then the corresponding dχ2(φ, µ) estimate will be
unreliable (and possibly poorly conditioned).
The chi-squared distances provide quantities that can be bench-
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marked but not directly interpreted.
2.7.6.6. Further evaluating SMC output
During the SMC runs, although the resource requirements of outputting
the entire particle distributions for each iteration would be excessive, it
is possible to output the particles periodically, not just at the final iter-
ation. It is helpful to output the full particle system at iteration 0, to
check that the prior distribution was correct and to help identify whether
any oddities seen in later iterations may have been caused by the specific
sample used in this initial iteration. Iteration one is also a very important
iteration as it is the first one that introduces the likelihood function. If
the tempering exponent (or number of iterations) is not well tuned then
the distribution after this iteration may either look too similar to the
initial distribution, suggesting that there may be many wasted compu-
tations in this iteration and following iterations, or it may be drastically
different from the initial distribution suggesting that the assumption of
being close has been violated and so the distribution from the first iter-
ation may not be accurate, not least because only a few particles from
the initial iteration will have survived, resulting in particle degeneracy.
Obviously the final particle distribution is the target distribution in this
setting, and so needs to be output in full so it can be thoroughly ana-
lysed. It may also be helpful to output one or more iterations mid-way
through the SMC run, e.g.
⌊
T/2
⌋
.
Further, it is possible to output details about every iteration, such
as: the average acceptance rate, the survival diagnostic, the proposal
variance, summary statistics for each of the posterior parameters, the
chi-squared distance between the current and next iteration, whether
resampling was performed, and details of a particle with maximal density.
These details will make it much easier to notice if anything looks unusual,
and make it easier to identify where and what may have gone wrong.
If the SMC sampler is executed with a large number of particles,
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then care needs to be taken when analysing the resulting particles: the
memory requirements of loading all the particles into memory on a stand-
ard PC can exceed the capability of the machine, and Windows is espe-
cially bad at remaining responsive during (or recovering from) low avail-
able memory situations.
Obviously, SMC is used mostly when the posterior cannot be eval-
uated analytically, and so the SMC estimate cannot be compared with
the actual posterior. However, it is helpful to run the SMC sampler for
simpler situations where the posterior can in fact be evaluated analytic-
ally, to check that the results are correct in those cases, and to get a feel
for the behaviour and variance of the sampler and things to look out for.
The same can be done in cases where the posterior cannot be evaluated
analytically but where features of the posterior are known, and it can
then be checked whether the SMC sampler has correctly captured those
features. See the next subsection for details where this was done.
Finally, if the output from the SMC sampler looks like it might poten-
tially correspond to the correct target distribution, it is wise to increase
the number of SMC iterations and/or the number of particles by an order
of magnitude, and to check that the resulting estimates are similar. This
need only be done once or twice for every model, and not necessarily for
every set of input data.
There are of course ways to test whether two independent samples
may have come from the same probability distribution, and to test
whether a sample may have come from a particular known probabil-
ity distribution. In one-dimension, the Kolmogorov-Smirnov test for two
independent samples and the Kolmogorov-Smirnov goodness-of-fit test
[91] are such possibilities, and do not assume that the error follows a
normal distribution. In higher dimensions, similar tests are somewhat
harder [92] and there has not been time to apply these in this work.
Visualisation of multi-dimensional distributions can be difficult, but
marginal distributions are trivial to extract from the weighted particle
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collections output by the SMC sampler, so it is generally worth plot-
ting marginal and pairwise marginal distributions for all the parameters.
These marginal distributions can often indicate features and/or likely
problems with the calculated posterior distribution. Scatter plots can
also be used if desired, provided that either the particles are resampled
first to have uniform weights or particles are shown with markers whose
sizes are relative to their weights.
2.7.6.7. SMC examples on simple low-dimensional models
As mentioned in the previous subsection, the SMC sampler should be
tested in situations where the true target distribution is known exactly,
so the sampler can be evaluated for performance and accuracy, before it
is applied to distributions that are less straightforward to verify.
With this in mind, the SMC sampler described was applied to a struc-
turally globally identifiable 2-compartment model with 2 parameters con-
sidered unknown. As this is a 2-dimensional problem, the results are easy
to see visually in 3-dimensions. This was the model depicted in Figure 2.4
with αb = 2.6287, k2,1 = 4.02488, ke,1 = 0 and both u(t) = Dδ(t) (an
impulsive input) with D = 4362.76 and ke,2 = 1.53968 were considered
known. Initially, the sampler was applied to noise-free observations from
this model, and because the observations were noise free, the above (nor-
mally excessive) accuracy stated in the parameters could be recovered by
the sampler.
The correct posterior distribution, computed directly, is shown in
Figure 2.6, and the smoothed output from the SMC sampler with 1,000
iterations, 10,000 particles and tempering exponent 2 is shown in Fig-
ure 2.7. The two plots have slightly different scales but appear to be
in agreement. As mentioned in the previous subsection, a statistical
test would ideally be performed here to check quantitatively whether the
SMC output appears to be a sample from the reference probability dis-
tribution, the true posterior. The author is aware that such a test is not
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straightforward in more than one dimension and so presently relies only
a visual calculation.
N Figure 2.6: 3D density plot of known correct posterior
distribution from model used for testing
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N Figure 2.7: Smoothed 3D density plot of output from
SMC sampler applied to known-posterior
testing model with 1,000 iterations, 10,000
particles, tempering exponent 2
With insufficient iterations with respect to the 2 compartment model
with 2 unknown parameters, the particle system output by the SMC
sampler misrepresented the true posterior distribution by showing the
distribution to have a lower variance than it actually does. Of course,
this may not be the only way that insufficient iterations generally affect
the output. The histogram in Figure 2.8 shows the output of the SMC
sampler when run with only 10 iterations, but with 10,000 particles. This
can be compared and contrasted with the true distribution in Figure 2.6.
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N Figure 2.8: Smoothed 3D density plot of output from
SMC sampler applied to known-posterior
testing model with 10 iterations (insuffi-
cient), 10,000 particles, tempering exponent
10
With insufficient particles with respect to the same situation, the
particle system output by the SMC sampler again misrepresents the true
posterior distribution by showing the distribution to have a number of
nearby modes instead of one distinct mode. The histogram in Figure 2.9
shows the output of the SMC sampler when run with only 1,000 particles
(but for 5,000 iterations).
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N Figure 2.9: Smoothed 3D density plot of output from
SMC sampler applied to known-posterior
testing model with 5,000 iterations, 1,000
particles (insufficient), tempering exponent
10
Clearly, it is necessary to choose carefully both the number of itera-
tions and the number of particles. A deficiency in the number of particles
cannot always be easily corrected by a modest (even geometric) increase
in the number of iterations, and vice versa. While a significant increase
in the number of iterations could potentially compensate for a low num-
ber of particles, this would be inefficient and difficult to justify compared
to increasing both the number of particles and the number of iterations
to an appropriate (but more modest) level.
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Chapter 3
New applications of statistical
analysis techniques
3.1. SMC and identifiability
As mentioned in subsection 2.5.6, it is not always possible to determine
the identifiability of a model algebraically. This may be because the al-
gebra becomes too complicated, or because the model does not admit a
rational polynomial expression. In such cases, although the identifiability
question cannot be definitively resolved structurally, it can be insightful
to consider the numerical identifiability of the model. Ideally, this numer-
ical identifiability information can be extracted using the same tool that
is used to perform parameter inference on a model, as the practitioner
can then observe numerical identifiability issues from whatever source in
the same way (e.g. issues caused due to the structural model, and also
issues caused due to the limitations in the data collection frequency or
noise).
As it has been suggested here that SMC is a good tool for model
inference, so it is now suggested that SMC can be applied to the numer-
ical identifiability problem. Whereas numerical optimisation techniques
usually only find one mode from each starting point (and it is not gen-
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erally feasible to find all modes, or to confirm that all modes have been
found), SMC estimates the entire posterior distribution and so if working
correctly will find all non-negligible modes, a key property that makes
it suitable for assessment of identifiability. However, it should be noted
that while numerical optimisation always seeks to identify the mode to
a given precision, SMC may only sample some particles in the vicinity
of the mode, and not find the mode exactly. If desired, it is of course
always possible to run a local optimisation method starting from the
nearby particles to identify the modes more precisely.
3.1.1. SMC applied to structurally unidentifiable
models
As illustrated in subsection 2.5.3, the 2 compartment model from Fig-
ure 2.4 is structurally unidentifiable when all the parameters are con-
sidered unknown (even considering αb as a combined parameter). For
this linear model, the same structural identifiability findings carry over
to the impulsive input case. The SMC sampler was therefore applied
to this model in this setting to determine the behaviour of the sampler
on a structurally unidentifiable model. The same parameter values as
in subsubsection 2.7.6.7 were used. One resulting approximation of the
posterior distribution is shown via the pairwise marginal density plots in
Figures 3.1 through 3.6.
Each of the pairwise marginal densities clearly show a ridge in para-
meter space as in Figure 3.1, or multiple ridges as in Figures 3.2–3.6. The
ridges arise from the fact that the parameters have one or more degrees
of freedom while still describing the same input/output function. If it
were not possible to conduct the structural identifiability analysis for this
model, the shape of the ridges could be used to infer the functional rela-
tionship between the parameters while keeping the input/output function
invariant. This information could then be used to assist the structural
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identifiability analysis.
N Figure 3.1: SMC results on a structurally unidentifiable model: marginal his-
togram density plot of bα and k21
N Figure 3.2: SMC results on a structurally unidentifiable model: marginal his-
togram density plot of bα, ke1
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N Figure 3.3: SMC results on a structurally unidentifiable model: marginal his-
togram density plot of bα, ke2
N Figure 3.4: SMC results on a structurally unidentifiable model: marginal his-
togram density plot of k21, ke1
80
3. New applications of statistical analysis techniques
N Figure 3.5: SMC results on a structurally unidentifiable model: marginal his-
togram density plot of k21, ke2
N Figure 3.6: SMC results on a structurally unidentifiable model: marginal his-
togram density plot of ke1, ke2
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3.1.2. SMC applied to structurally locally identifi-
able models
As shown in subsection 2.5.3, the 2 compartment model presented earlier
in Figure 2.4 is structurally locally identifiable (but not structurally
globally identifiable) when αb is treated as a combined parameter and
ke,1 = 0, while the remaining parameters are considered unknown.
With the same simulated data as previously, there are two indistin-
guishable parameter combinations:
1. the original parameter set αb = αb = 2.6287, k2,1 = k2,1 = 4.02488
and ke,2 = ke,2 = 1.53968; and
2. αb = αbk2,1
ke,2 = 2.6287, k2,1 = ke,2 = 4.02488, and ke,2 = k2,1 =
1.53968.
The SMC sampler was again applied to this model with ke,1 = 0
considered known and the remaining parameters considered unknown. A
resultant approximated posterior distribution is shown via the pairwise
marginal density plots in Figures 3.7 through 3.9. The plots clearly
show that the marginal distributions have two separated and well-defined
modes (though the large separation between them prevents display of
more detail in the vicinity of these modes), and it can be seen that
these modes occur exactly in the expected positions as revealed by the
structural identifiability analysis. This demonstrates that one possible
cause of having multiple but separated modes in the posterior distribution
could be structural local identifiability of the model. If it were not already
known, it would not be completely infeasible to identify the functional
relation between the parameters from the positions of the modes and
to use this information to confirm algebraically that the model is not
structurally globally identifiable.
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N Figure 3.7: SMC results on a structurally locally identifiable model: marginal
histogram density plot of bα, k21
N Figure 3.8: SMC results on a structurally locally identifiable model: marginal
histogram density plot of bα, ke2
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N Figure 3.9: SMC results on a structurally locally identifiable model: marginal
histogram density plot of k21, ke2
3.1.3. Using the posterior distribution to inform on
identifiability
A much quicker way to inform on overall practical identifiability is to
calculate the chi-squared distance between the target distribution and
an exponentiated copy of the target distribution (like a “tempered” dis-
tribution but raised to a power larger than 1), essentially extracting the
information directly from the computed posterior distribution. Raising
the posterior distribution to a power larger than 1 amplifies its peaks and
diminishes other regions, so if the posterior distribution has well-defined
peaks then there will be a large difference between it and the exponenti-
ated distribution. On the other hand, if the posterior distribution does
not have well-defined peaks (e.g. because it is practically unidentifiable),
then raising it to a larger power will not result in a significant difference,
and so the chi-squared distance will be smaller.
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Although this method requires significantly less computational re-
sources, and does not even require estimating the exponentiated distri-
bution, it does not inform on which parameters are problematic.
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3.2. SMC for computing profile likelihood-
s/posteriors
It is possible to compute “profile posteriors” for each of the parameters,
which would be useful for various purposes, including to examine those
profiles to determine the practical identifiability of the corresponding
parameters. Namely, if a profile is flat for large regions of the parameter
space, then the parameter is practically unidentifiable. If the profile
contains multiple peaks then there is a possibility of getting stuck in
a local mode. Conversely, if the profile has a distinct maximal peak,
and few smaller peaks, then that parameter is likely to be practically
identifiable.
However, computing these “profile posteriors” would appear to in-
volve solving a large quantity of optimisation problems, which would
again be infeasible. A more efficient approach would be to borrow in-
formation from one optimisation problem to help with the next such
problem, and this is indeed possible through SMC. Each iteration in
such a setup corresponds to a particular value of the ‘profiled’ parameter,
and the distribution at each iteration (or at least the particle with max-
imal posterior density) is of interest, as opposed to a standard SMC run
where only the final iteration is of real interest. Successive distributions
are similar because they only involve a small increment/decrement to
the profiled parameter. This also requires standard SMC runs to reach
the starting distribution for each parameter, before the profiling can pro-
ceed. However, calculating the profile posteriors through SMC somewhat
prevents those profile posteriors being used to help verify the original ap-
proximation of the target distribution as produced by SMC.
A rough implementation of this was attempted by the author but was
soon abandoned in favour of the preceding approach, as it was necessary
to discard previous SMC runs when switching from exploration mode
to profiling mode, and therefore was not considered efficient enough to
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justify its use.
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Chapter 4
Model development and
analysis
4.1. Pharmacokinetic model development
and analysis
The model from subsection 2.6.1 is revisited, and an extension is now
presented to the analysis thereof.
4.1.1. Structural identifiability
The structural identifiability of this model was previously considered in
Hall [1] and some of the following extensions to the results there were
presented in Hall et al. [2].
Let p denote the vector of unknown parameters in the model. Take
p =
(
b k21 k31 k42 k43 ke2 ke3 ke4 α1 α2
)T
, (4.1)
where the feasible parameter space is Ω := (0,∞)n 3 p, with n = 10
denoting the number of unknown parameters.
The observation function y is now written y(·,p) to emphasise its
dependence on the unknown parameters.
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The structural identifiability of this model was analysed using the
Laplace transform approach [54] in Hall [1], one of the most commonly
used methods for linear time-invariant systems, where it was found that
ke4 is SLI with either ke4 = ke4 or ke4 = k43 + ke3, and all other model
parameters are SUI. Additional assumptions were then considered to see
if they constrain the system model to be structurally identifiable. A
slight modification of those assumptions is presented below:
(a) Other studies have reported apparent volumes of distribution for
ARS and DHA following oral administration of ARS. In particular,
Morris et al. [39] report the median volume of distribution for ARS
at 6.8 l/kg and 1.55 l/kg for DHA in malaria patients (though these
are noted to vary significantly relative to severity of infection). Such
information can be used to treat the ratio of the observation gains
as known; that is, r := α2/α1 is known (α1 = α and α2 = rα, say).
Using the above information from Morris et al. [39], this would give
r = 4.387 (the observation gain for DHA is larger because it has
the smaller volume of distribution);
(b) There is no known reason to suggest that the metabolism of the
ARS occurs at significantly different rates before and after absorp-
tion, so it might be valid to consider the metabolism rate constants
to be equal: k31 = k42;
(c) There are no other major metabolites of DHA and negligible quant-
ities of ARS are detected in urine. Hence, ARS is almost entirely
converted to DHA, and so it may be reasonable to assume that the
elimination rate parameter ke2 = 0;
(d) Absorption of the metabolite is rapid, thus its elimination may be
negligible before it is absorbed, i.e. ke3 = 0.
Note that when constraints of this sort are imposed on paramet-
ers, the corresponding models are considered to be structurally distinct;
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structural identifiability is concerned with the behaviour of almost all
parameter values, and these assumptions may mean that previously null
sets now have strictly positive measure.
Each combination of these four assumptions was assessed (or if con-
sidered previously, then re-assessed) using the same methods as previ-
ously, and the structural identifiability results are tabulated in Table 4.1.
It can be seen that applying just one of the additional constraints does
not improve the structural identifiability for the majority of the para-
meters. Applying any combination of two constraints except α2/α1 = r
and ke2 = 0 constrains all the parameters to be at least structurally loc-
ally identifiable. Applying any combination of three of the assumptions
constrains the model to be structurally globally identifiable. The assump-
tion (b) that k31 = k42 seems to be the weakest in terms of improving
structural identifiability.
4.1.2. Statistical analysis
4.1.2.1. Weight cap
Hall [1] did not use the described weighting matrix for the data, so the
use of that matrix was evaluated here. However, as was anticipated, due
to the wide range in concentrations reported for individual patients over
the studied time interval, parameter fitting using the weighting matrix
corresponding to the reported errors (see subsection 2.7.2) did not yield
good fits. When using errors corresponding to predicted observations in
contrast to weighting by actual observations, high concentrations were
artificially predicted, corresponding to low weights. These points could
thus be missed completely with little penalty on the likelihood. Prior to
conducting the analysis, this outcome was anticipated and it was planned
that the condition number of the weighting matrix might need to be
controlled to resolve this. The singular values of the weighting matrix
(to cater for the cases where the matrix was not diagonal due to the
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Assumptions Structural identifiability results
α2
α1
= r
r known
k31 = k42 ke2 = 0 ke3 = 0 k21 k31 k42 k43 ke2 ke3 ke4 bα1 bα2 bα
0 0 0 0 U U U U U U L U U -
0 0 0 1 U U U L U - L U U -
0 0 1 0 U U L U - U L U U -
0 0 1 1 L L L L - - L L L -
0 1 0 0 U - U U U U L U U -
0 1 0 1 L - L L L - L L L -
0 1 1 0 G - G L - L L G L -
0 1 1 1 G - G G - - G G G -
1 0 0 0 U U L U L U L - - U
1 0 0 1 L L L L L - L - - L
1 0 1 0 U U G U - U G - - U
1 0 1 1 G G G G - - G - - G
1 1 0 0 L - L L L L L - - L
1 1 0 1 G - G G G - G - - G
1 1 1 0 G - G G - G G - - G
1 1 1 1 G - G G - - G - - G
The applicable parameters under any combination of the assumptions (1
if the assumption is applied and 0 if not) are either structurally uniden-
tifiable (U), structurally locally identifiable (L) or structurally globally
identifiable (G).
Table 4.1: Structural identifiability analysis results for the
four compartment model under different com-
binations of constraints
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assumption of correlation between different measurement errors) were
therefore capped so that no singular value exceeded 100 times the lowest
singular value, resulting in the condition number of the weighting matrix
becoming at most 100. Imposing this cap yielded much improved model
fits, and so only these improved fits are presented here.
Even with this cap, the objective function had multiple local minima
for many patients, and often had multiple local minima achieving similar
objective function values but considerably different parameter estimates.
In these cases, the global minimum was usually selected, except in a
minority of cases where the fitted parameter values were extreme and a
local minimum was identified that seemed more realistic. This highlights
the fact that having a globally identifiable model structure is a necessary
but not sufficient condition to ensure practical identifiability, especially
in the presence of high model and observation errors.
4.1.2.2. Maximum likelihood results
Observations and model fits for one of the patients (“Patient A”) are
shown in Figure 4.1 together with model predictions of the quantities in
the absorption compartments. The corresponding parameter values and
measures of their uncertainty are presented in Table 4.2 and Table 4.3.
The confidence bands give an indication of the sensitivity of the fit.
It can be seen that the model fit for patient A appears to be satis-
factory. Not all model fits were satisfactory for all patients. For brevity,
results for the other patients are not presented here in the same way,
but instead model fit results are summarised through the coefficient of
determination and shown in Figure 4.2, and a summary of parameter
estimates across all patients is provided in Table 4.4. The worst model
fits correspond to patients whose observed ARS and DHA concentration–
time profiles did not both reach peaks within 3 hours of dose administra-
tion, or those where at least one of the drugs exhibited multiple peaks
(approximately half of the patients exhibited one of these issues, and are
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N Figure 4.1: Example of model predicted ARS and DHA quantities/concentra-
tions in each compartment for patient A using the 4-compartment
pharmacokinetic model. Error bars are representative of assay er-
ror. Confidence bands are also shown but are very narrow.
Parameter Fitted value Standard error Units
bα 0.2330 0.0105 kg/l
r 4.3870 (fixed) dimensionless
k21 1.2518 0.0863 h−1
k42 2.0378 0.0199 h−1
k43 0.4604 0.0113 h−1
ke4 0.9975 0.0426 h−1
ρ 0.0207 (nuisance) correlation
Objective function value 3747.23
Coefficient of determination 96.46 %
Table 4.2: Table of parameter estimates and their uncer-
tainties for patient A using the 4-compartment
pharmacokinetic model.
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Parameter correlation matrix (darkness of black/red colour corresponds to
strength of positive/negative value in each cell respectively):
bα k21 k42 k43 ke4
bα 1.000 −0.977 0.199 −0.767 0.994
k21 −0.977 1.000 −0.292 0.638 −0.982
k42 0.199 −0.292 1.000 −0.021 0.187
k43 −0.767 0.638 −0.021 1.000 −0.712
ke4 0.994 −0.982 0.187 −0.712 1.000
Table 4.3: Correlation matrix for the parameters in
Table 4.2 for the 4-compartment pharmacokin-
etic model.
−20 0 20 40 60 80 100
N Figure 4.2: Distribution of the coefficient of determin-
ation (%) over the Mahidol_PK dataset;
marks in red correspond to patients with un-
expected profiles. Recall that the objective
was not to maximise the coefficient of de-
termination, but this statistic allows easier
comparison between subjects than the actual
objective function values.
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coloured in red in Figure 4.2). Note that the fit for one such patient
has a negative coefficient of determination. This does not necessarily
suggest that fitting the mean to the concentration–time profile of each
drug would have performed better than fitting the model (although that
is a natural interpretation), because the model still captures part of the
absorption and elimination processes and therefore their shapes, though
model predictions should not be relied upon in these circumstances. The
coefficient of determination statistic was used to help quantify the good-
ness of the model fits, but it does not provide a good interpretation of
the results: there is no direct correlation between this statistic and the
likelihood function used. In particular, the objective criteria was not to
maximise the coefficient of determination. These results suggest that it
would be useful to compare the influence that the normal distribution
had vs. Student’s t-distribution or the Laplace distribution: see subsec-
tion 2.7.2 and section 5.1.
Parameter Mean (SD) Units
bα 0.472 (0.32) kg/l
r 4.387 (fixed) dimensionless
k21 0.281 (0.30) h−1
k42 1.119 (0.74) h−1
k43 0.835 (0.59) h−1
ke4 1.612 (1.28) h−1
CoD weighted 74.25 (28.8) %
ARS half-life 0.93 (0.58) h
DHA half-life 0.72 (0.53) h
Table 4.4: Fitted parameter values, aggregated
The parameter estimation procedure was typically insensitive to the
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correlation parameter ρ (perhaps as a result of the weight cap) and this
parameter was often fitted close to 0 even when not used as the initial
value for the optimisation. Having preferred a local minimum over the
global minimum in some cases, no individual parameter estimates were
unreasonable in isolation. However, the parameter estimates were not
always considered well determined and many varied significantly between
patients.This was most marked for k21, where the largest and smallest
estimated values differed by a factor of 100, while the other parameters
varied by roughly a factor of 10. The wide variability in the patient
profiles makes it possible that (though unclear whether) this is plausible,
and could be due to differences in the severity of the malaria, issues with
the quality of the data, or other covariates (such covariates were not
available for evaluation here).
Many people working in the field prefer to express elimination para-
meters in terms of half-lives. From the parameters in the parameter
vector p, the ARS half-life can be calculated as
t 1
2 ,ARS
= ln 2/(k42 + ke2), (4.2)
and the DHA half-life as
t 1
2 ,DHA
= ln 2/ke4. (4.3)
Estimates of these parameters obtained here (shown in Table 4.4) agree
in range with those summarised in Morris et al. [39] (0.36–1.2 hours for
ARS and 0.49–3.08 hours for DHA), but while Morris et al. [39] report
that the DHA half-life is consistently longer than that of ARS, the same
result was not found for all of the patients in this study; the reasons for
this are unclear.
Model fitting was also conducted by relaxing one constraint at a time
(still resulting in SGI model structures) to assess the effect on the para-
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meter estimates. Doing so either did not significantly alter the parameter
estimates, or otherwise did not generally improve fits visually (sometimes
making them appear noticeably worse), and only marginally reduced the
objective function values. The resulting estimates for some parameters
were very close to their constrained values in some cases, while in others,
the parameter estimates changed significantly and inconsistently, and
their associated uncertainties increased also. When this occurred, the
changes propagated to the other parameters too (due to the correlation),
resulting in even wider variability of the parameters between patients.
These results therefore provide evidence suggesting that the constraints
imposed are as reasonable as could be hoped.
4.1.2.3. Sequential Monte Carlo results
The Sequential Monte Carlo sampler described in subsubsection 2.7.6.1
was also applied to the four compartment pharmacokinetic model to ex-
plore both the model and data in more detail and to gain more experience
with the SMC sampler. Independent uniform priors were assumed for all
parameters, truncated to the plausible range to ensure the prior was
proper and to improve the behaviour of the sampler compared to using
a larger space.
SMC estimated posterior marginal distributions for each of the para-
meters are presented in Figures 4.3 through to 4.7.
0.0592 0.0594 0.0596 0.0598
1000
2000
3000
bioTimesAlpha
N Figure 4.3: SMC estimate of posterior marginal distri-
bution for bα for patient A
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N Figure 4.4: SMC estimate of posterior marginal distri-
bution for k21 for patient A
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N Figure 4.5: SMC estimate of posterior marginal distri-
bution for k42 for patient A
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N Figure 4.6: SMC estimate of posterior marginal distri-
bution for k43 for patient A
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N Figure 4.7: SMC estimate of posterior marginal distri-
bution for ke4 for patient A
Pairwise marginal distributions have also been extracted and are
shown in section A.1 to prevent cluttering this section. The model fits
corresponding to the point with maximal posterior density are shown in
Figures 4.8 and 4.9. It can be seen that the residuals for these plots are
smaller than those in the previous fit (Figure 4.1).
2 4 6 8 10 12
Time
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ARS
N Figure 4.8: ARS model fit using point with maximal pos-
terior density for patient A
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500
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1500
Conc
DHA
N Figure 4.9: DHA model fit using point with maximal
posterior density for patient A
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4.2. Coupled parasite lifecycle model
4.2.1. Model development
As mentioned previously in section 2.3, a model must be designed with
reference to the available data. A goal of this chapter is to model the
data from subsection 2.3.3. Recall from that section that some patients
were administered mefloquine in addition to artesunate on days 3 and 4.
As the pharmacokinetic data for mefloquine are unavailable, it is difficult
to model beyond day 3 for those patients and so this has not been done
here.
It was previously concluded that there are changes in the stage-
specific efficacy of the artemisinin derivatives between the two sites. It is
therefore important that the model designed here is capable of capturing
the same behaviour, and it will be interesting to observe whether the
same effect is found.
The model is designed to be able to make use of in vitro data to help
calibrate parameters that would otherwise be unidentifiable.
As the model is non-linear, unlike the pharmacokinetic model in sub-
section 2.6.1, it will be necessary to use the full quantity of drug admin-
istered as input to the model, rather than the per kg amount. Fortu-
nately, the dataset contains the necessary data for this to be possible.
The most difficult part of the modelling was to ensure that the para-
sites’ lifecycle is described continuously without having the effect of in-
stantaneous ageing. It was initially thought that discrete-time models
would be necessary for this, or models where each parasite replicate had
an age parameter associated to it (which due to the large number of
parasites initially present would be intractable), but a solution involving
“shadow compartments” was found. This will be described in more detail
in the relevant subsection.
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4.2.2. Model
A novel model coupling the drug pharmacokinetics and the parasite life-
cycle is proposed. The model structure has been tailored to correspond
with the available data (see subsection 2.3.3), but no attempt is made
to model the mefloquine kinetics or dynamics: data only for days prior
to mefloquine administration will be used. Model predictions can be
generated for the following days assuming mefloquine had not been ad-
ministered, to examine the effect that the addition of mefloquine has
had.
Although this model is an extension of the model in subsection 2.6.1,
previous assumptions on those rate constants that are analogous will have
to be revalidated or replaced.
The system model is not strictly compartmental so the system dia-
gram has to be interpreted with care.
In introducing the model, it is helpful to first look at a subsection of
it:
4.2.2.1. Submodel
The proposed model essentially contains a submodel consisting of the
plasma, red blood cell and parasite dynamics. It is simpler to present
this submodel for a single drug first; see Figure 4.10. The in vitro data
can be modelled by this submodel as an initial step, before considering
the full model.
The submodel contains 4 compartments, of which 3 represent the
location of the drug: a plasma compartment, a red blood cell (RBC)
compartment, and a parasite compartment. The parasite compartment
in fact represents the bound form of the drug, after binding with receptors
in the parasites. Representing the pool of available receptors in the
parasites as the 4th compartment therefore completes the selection of
model states.
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The drug in the plasma compartment is modelled as flowing by dif-
fusion to and from the red blood cells. Ligand-receptor kinetics are then
used to describe the binding of the drug inside the red blood cells to the
parasitised portion of the red blood cells. Although radio-labelled stud-
ies have shown that drug bound to the parasites does not appear to be
displaced, it is not known a priori whether it is possible for the drug to
dissociate from the parasite receptors, albeit very slowly, or whether no
dissociation can occur at all. The model therefore leaves in the possib-
ility of dissociation, which is effectively removed when the dissociation
rate constant is zero.
The in vitro study measures the proportion of uptake of the radio-
labelled artemisinin in the “pellet” compared to the total (pellet plus
supernatant) after centrifuging. The pellet therefore includes the red
blood cells and the parasites within the red blood cells, while the super-
natant corresponds to the plasma.
The parameters in this submodel and their meanings are listed in
Table 4.5.
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2. plasma 5. RBCs,
diffusion
7. parasites
inside RBCs
r. parasite
receptors
y1(t) =
q5(t)+q7(t)
q2(t)+q5(t)+q7(t)
k52(t)
k25(t)
k7(t)
k−a/ζ
k7(t) k−a/ζ
= artemisinin (or derivative), = linear non-zero flow (with
hematocrit fixed), = non-linear (i.e, non-constant transfer coefficient).
= coupled to parasite parameters.
N Figure 4.10: In vitro submodel for drug uptake into red
blood cells
The compartments within the model are numbered to correspond to
those in the full model. The model is parameterised in terms of the
haematocrit ζ (considered proportional to the number of RBCs), para-
sitaemia percentage p, and the total volume of blood v2. These are con-
sidered static parameters for the in vitro experiments (rather than poten-
tially changing with time). The initial concentration of the drug in the
plasma is a known initial condition of the model, while the initial number
of parasite receptors is only known up to a constant of proportionality.
In the in vitro experiments, the volumes of blood and parasitaemia are
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known, but the parasite lifecycle stage is not measured. Therefore, for
simplicity and identifiability, the infected red blood cell compartment is
not split by parasite stage.
The equations for the submodel are as follows:

q′2(t) = µ
(
q5(t)
v5
− q2(t)
v2
)
q′5(t) = −µ
(
q5(t)
v5
− q2(t)
v2
)
− kaq5(t)qr(t)
ζ
+ k-aq7(t)
ζ
q′r(t) =
k-aq7(t)
ζ
− kaq5(t)qr(t)
ζ
q′7(t) =
kaq5(t)qr(t)
ζ
− k-aq7(t)
ζ
q2(0) = c0v2
q5(0) = 0
q7(0) = 0
qr(0) = κζp
y1(t) = q5(t)+q7(t)q2(t)+q5(t)+q7(t)
(4.4)
where v5 = ζλc, v2 = 0.7 ml. i.e. in the above diagram,
k52(t) = max
{
µ
(
q5(t)
v5
− q2(t)
v2
)
, 0
}
k25(t) = max
{
−µ
(
q5(t)
v5
− q2(t)
v2
)
, 0
}
k7(t) = kaq5(t)qr(t)/ζ.
(4.5)
The parameter λc provides an extra degree of freedom for the concen-
trations in red blood cells and whole blood to differ by a fixed ratio.
The in vitro data are only available for artemisinin, so the submodel
will be initially calibrated based on this, though adjustments may have
to be made for the different derivatives used in the full model (artesunate
and dihydroartemisinin). The calibration of the submodel to the data
is made under the assumption that the radio-tracer stayed bound to
the artemisinin, which therefore includes the assumption that there was
no metabolism of artemisinin, either into other artemisinin derivatives
or into inactive metabolites. This assumption is necessary given the
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limitations of the data provided, and will still produce useful insight.
However, before incorporating parameters derived from these data into
the full model, consideration should be given to necessary corrections,
including the corrections already necessary for the different derivatives.
4.2.2.2. Submodel structural identifiability
Before attempting to fit the in vitro data to the submodel, it is important
to first check that the model is structurally identifiable. The model is an
uncontrolled model with 5 unknown parameters, 3 known parameters,
and no input. The model parameters are summarised in Table 4.5.
Parameter Description Known/unknown
κ number of receptors per unit of infected hematocrit unknown
ka drug-parasite receptor binding rate constant unknown
k-a drug-parasite receptor unbinding rate constant unknown
µ permeability of red blood cells unknown
λc concentration factor for diffusion equilibrium unknown
ζ hematocrit known
c0 initial concentration of drug known
p parasitaemia known
v2 total volume of blood known
Table 4.5: Table of parameters in the artemisinin red blood
cell uptake submodel
The Taylor series method is easily applied to this model. Calculating
six Taylor series coefficients of the observation function shows the model
to be structurally globally identifiable.
It may be of interest to also determine the situation when used with
only uninfected red blood cell data, i.e. when p = 0. Re-applying the
same method under these circumstances, only µ and λc are found to be
structurally globally identifiable, with the remaining unknown paramet-
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ers κ, ka and k-a being structurally unidentifiable (in fact, not appearing
in derivatives of the output function at all to any order checked, though
it is noted that this method is technically inconclusive unless all Taylor
series cofficients are checked), as would be expected.
4.2.2.3. Submodel parameter estimates
Based on the above structural identifiability analysis, it would clearly be
possible (under the assumption of continuous noise-free data) to estimate
parameters µ and λc from the uninfected red blood cell data, and then
to consider these parameters as known when estimating the remaining
parameters from the infected red blood cell data. However, there are few
data points available and it is probably more helpful to estimate all the
parameters using all the data, so that is what was done here.
Parameter estimates were determined using the in vitro data for
artemisinin (introduced in subsection 2.3.2) and are shown in Table 4.6,
and the corresponding model predictions are shown in red in Figures
4.11 through to 4.17. Note that the same parameters are used to gen-
erate all plots (excepting the independent parameters ζ, p, c0), so that
even though some plots do not look to have fitted perfectly, the reason
for that is the model has been constrained by the data points shown in
the other plots. The systematic error that appear consist of too-high
model estimates in some plots, and too-low model estimates in others,
suggesting that the fitting has performed as well as it can under the con-
straints. It was unknown whether the flow described by parameter k-a
was in fact present in the system being modelled. The numerical optim-
iser was estimating parameter k-a to be close to 0 (around 10−9) so this
parameter was instead forced to 0 to improve estimates of the remaining
parameters.
As noted earlier, these data are for artemisinin and so these para-
meters cannot necessarily be used directly for ARS or DHA, but if the
model behaves well for artemisinin then an appropriate change to the
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parameter values should render it suitable for those other derivatives.
As this derivative is not of much interest here, a full statistical analysis
is not carried out. It is sufficient to determine visually whether the model
is behaving appropriately.
Parameter Description Value
κ number of receptors per unit of infected hematocrit 14,500
ka drug-parasite receptor binding rate constant 0.00225
k-a drug-parasite receptor unbinding rate constant 0 (forced)
µ permeability of red blood cells 5.58
λc concentration factor for diffusion equilibrium 1.12
Table 4.6: Table of parameter estimates in the artemisinin
red blood cell uptake submodel
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0.1
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0.3
0.4
0.5
% partitioning Hematocrit vs partitioning
N Figure 4.11: Hematocrit against partitioning coefficient
for uninfected cells (with c0 = 880 nM, t =
2 hours, p = 0%), data and model
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N Figure 4.12: Incubation time (hours) against partition-
ing coefficient for uninfected cells (with
c0 = 1410 nM, ζ = 33%, p = 0%), data
and model
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N Figure 4.13: Initial concentration against partitioning
coefficient for uninfected cells (with t = 2
hours, ζ = 33%, p = 0%), data and model
108
4. Model development and analysis
0.1 0.2 0.3 0.4
hematocrit
0.1
0.2
0.3
0.4
0.5
0.6
0.7
% partitioning Hematocrit vs partitioning (infected)
N Figure 4.14: Hematocrit against partitioning coefficient
for infected cells (with c0 = 880 nM, t = 2
hours, p = 6%), data and model
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It is clear that the model appears to capture the correct shape of the
behaviour for each ‘slice’ of the available data. Some systematic errors
are clearly seen in the uninfected haematocrit and uninfected incubation
time slices, with under- and over-estimates of the data, respectively. It is
also clear that the first data point for measuring uptake against time was
too late to capture the initial uptake period (or rather, the uptake was
so fast so as to prevent observation of this), so it seems that it should be
hard to calibrate the uptake parameter µ exactly. Although no problems
were reported by the numerical optimisation scheme used, no sensitivity
analysis was conducted.
110
4. Model development and analysis
4.2.2.4. Ageing model
As the lifecycle stage of the parasites plays a key role in both the time
of replication of the parasites, and in the drug-parasite interactions, it
is necessary to model the lifecycle stage of the parasites, or equivalently,
their ages. There can be in excess of 1012 parasites in total in severe
cases, corresponding to 200,000 parasites per microlitre of blood [93]. The
parasites are also often synchronised or near-synchronised. It is therefore
neither feasible nor particularly useful to keep track of the age of each
individual parasite: keeping track of the lifecycle stage is a sufficient and
simpler alternative.
To decide on the appropriate lifecycle stages to lump parasites into,
first recall that there are 4 age classes into which malaria parasites are
often distinguished: merozoites (∼ 2 mins), ring forms (∼ 12 hours),
trophozoites (∼ 24 hours) and schizonts (∼ 12 hours). From a modelling
perspective, the merozoites are transient; existing only on a negligible
time scale relative to the remaining stages and time scales of the drug
model, hence merozoites need not be incorporated as a distinct stage but
parasites in this form can be lumped into either of the adjacent stages.
The remaining three stages have different durations, and the susceptibil-
ity of the young and mature ring forms is thought to differ. Hence, it is
helpful to reassign the stages to be more practical for the purposes of the
model, and such that each has a similar duration. Eight age classes are
therefore used, each of 6 hours duration: young ring forms, mature ring
forms, young circulating trophozoites, mature circulating trophozoties,
youngly sequestered trophozoites, mature sequestered trophozites, young
schizonts and mature schizonts. There is thought to be little value in hav-
ing age classes of shorter duration, due to the synchronous nature of the
parasites and the forseeable difficulty in the practical identifiability of
stage-specific parameters for shorter age classes.
Now that the age classes have been decided upon, the actual mech-
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anics of the progression between age classes needs to be elucidated. In-
stantaneous progression of parasites from one age class to the next might
be simple to model but, even if parasites are generally age-synchronised,
this would be an undesirable property because there would be sudden
discontinuous jumps in the numbers of parasites due to parasite death
and replication. Hence a continuous-time model of ageing would be pre-
ferred. The simplest such model that occurred to the author consisted of
each age class connected in series to its successor, in the standard first-
order manner as is usual for many compartmental models. However, it is
clear that first-order kinetics can only account for the mean behaviour of
essentially exponentially distributed holding times (or extensions thereof
with moderate complexity such as Erlang distributions) [94]. Such hold-
ing time distributions have non-zero probability densities for all positive
times, and so are not really suitable to describe ageing. For instance,
some non-zero proportion of the parasites age instantaneously in these
models, and to make this proportion negligible requires a large number
of intermediate compartments, which becomes infeasible.
It is possible to maintain continuous-time behaviour without this dif-
ficulty, however, by specifying that the flow rates between age classes
undergo discrete-time step changes. Specifically, to describe a 48 hour li-
fecycle using eight age classes of equal duration, the eight age classes can
be represented with two compartments each; one acting (at any given
time) as a ‘live’ compartment and one as a ‘shadow’ compartment for
each, giving 16 compartments in total. The terms ‘live’ and ‘shadow’
compartments are slightly misleading as their roles periodically altern-
ate, but the ‘live’ compartment can be thought of as ‘initially live’ when
t = 0 (i.e. when modelling begins) and the other as ‘initially shadow-
ing’. Live and shadow compartments are symmetrical in terms of their
equations and hence equivalent in nature, just it is convenient to give
them names that highlight the fact that they represent part of the same
measured quantity (parasites in a certain age class). The distinction is
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that the live compartment represents parasites prior to the transition to
the next age class, and the shadow compartment represents those after
the transition has completed (or vice versa, depending on the stage in
the periodic cycle).
As the ageing is to happen continuously rather than instantaneously,
a time window τchange for ageing must be chosen, e.g. the advancing from
one age class to the next could take place over a window of length τchange =
1 hour, say. Suppose that at t = 0, the parasites were already δt hours
into their current age classes. i.e. in the age class of 0–6 hours, all the
parasites are ∼ δt hours old, and similarly those in the 6–12 hour age
class are all ∼ 6 + δt hours old, and so on. The advancement process
then could be modelled as taking place between time 5.5−δt and 6.5−δt
hours, every 6 hours. Generally, the switching begins τchange/2 time units
before the lifecycle duration is reached, and completes τchange/2 time units
after. This is achieved in the model by toggling on a flow during that
time interval, such that the parasites in the ‘live’ compartments move to
the age-advanced ‘shadow’ compartments, as shown in Figure 4.18. (In
the next time interval 6 hours later, the flows are from these ‘shadow’
compartments into the ‘live’ compartments, as their roles have reversed.)
Zeroth-order (constant) dynamics are chosen, but once all the parasites
in the donor compartment have migrated (or died), that particular flow
is toggled back to 0.
A background rate of parasite kill is specified here for illustrative
purposes. This is replaced with a drug-dependent rate in the full coupled
model.
At the beginning of the discrete event at time t∗ with · representing
either the live compartments l or the shadow compartments s as appro-
priate, set k(·)i ← p(·)i (t∗)/τchange where τchange is the time interval over
which the ageing process takes place. (To validate this, note that the
time domain equation for the contribution of the zeroth-order ageing
flow after τchange hours is −kiτchange, which with the above definition of
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ki is equal to −p(·)i . i.e. this corresponds to all parasites having left the
compartment. Of course, with background/drug-induced death, it may
not take τchange for the compartment to become empty, but the ageing
rates are still defined in this way.)
The differential equations governing the parasite lifecycle model are
conceptually simple:
p
(l)
1
′
(t) = −d1p(l)1 (t)− k(l)1 +Mk(s)8
p
(l)
2
′
(t) = −d2p(l)2 (t)− k(l)2 + k(s)1
p
(l)
3
′
(t) = −d3p(l)3 (t)− k(l)3 + k(s)2
p
(l)
4
′
(t) = −d4p(l)4 (t)− k(l)4 + k(s)3
p
(l)
5
′
(t) = −d5p(l)5 (t)− k(l)5 + k(s)4
p
(l)
6
′
(t) = −d6p(l)6 (t)− k(l)6 + k(s)5
p
(l)
7
′
(t) = −d7p(l)7 (t)− k(l)7 + k(s)6
p
(l)
8
′
(t) = −d8p(l)8 (t)− k(l)8 + k(s)7
p
(s)
1
′
(t) = −d1p(s)1 (t) +Mk(l)8 − k(s)1
p
(s)
2
′
(t) = −d2p(s)2 (t) + k(l)1 − k(s)2
p
(s)
3
′
(t) = −d3p(s)3 (t) + k(l)2 − k(s)3
p
(s)
4
′
(t) = −d4p(s)4 (t) + k(l)3 − k(s)4
p
(s)
5
′
(t) = −d5p(s)5 (t) + k(l)4 − k(s)5
p
(s)
6
′
(t) = −d6p(s)6 (t) + k(l)5 − k(s)6
p
(s)
7
′
(t) = −d7p(s)7 (t) + k(l)6 − k(s)7
p
(s)
8
′
(t) = −d8p(s)8 (t) + k(l)7 − k(s)8
where the k rate parameters are driven by discrete events. The discrete
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events are:
when p(·)i reaches 0, set k
(·)
i ← 0
when t+ toffset ≡ 0 mod 12, set k(s)i ← p(s)i (t)/τchange
when t+ 6 + toffset ≡ 0 mod 12, set k(l)i ← p(l)i (t)/τchange.
The di terms represent first-order parasite death rates, which in the
full model are coupled to the pharmacokinetics of the drugs, but for illus-
tration here they consist solely of a constant background death rate. The
model also incorporates a further discrete event to ensure if the density
of the parasites falls below a predefined threshold, then the infection has
effectively died out. Without this extra event, after enough cycles in the
absence of a significant background/drug-induced death rate, the para-
sites might be shown to return to a substantial density under the model,
which isn’t always observed. The threshold can of course be configured
to a plausible value.
Figure 4.18 shows the compartments representing the age stages
within the lifecycle and the connections between the live and shadow
compartments.
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N Figure 4.18: Parasite lifecycle model showing connectivity between live and shadow compartments.
The solid flows are always enabled. Either the dashed green flows or the dashed teal flows are active
(until the respective donor compartment runs out of parasites), both sets of dashed flows are never
active simultaneously. The number of parasites in a given age class is always taken to be the sum of
the quantities in each of the live and shadow compartments for that age class.
Compartments with a grey background are observable, while compartments with a white background
are unobservable as they represent sequestered stages of the lifecycle.
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An example of the behaviour of this parasite lifecycle model is shown
in Figure 4.19. For this figure, the model was started with a single ini-
tial parasite population entirely within age class 1, and uses constant
background death rate parameters. In the figure, it can be seen that the
parasites that initially started in age class 1 move into the successive age
classes after the expected time intervals. Figures 4.20 and 4.21 show the
aggregated time courses of total and observable parasite densities across
the age classes, respectively. The effect of the background parasite death
rate can be seen, which stops the parasite population from exploding.
It is also clear that the unobservability of the sequestered parasites has
a significant effect on the observed parasitaemia, and that even though
it may appear that all the parasites have died, this is not necessarily
the case. Observations must therefore be made of parasitaemia at suf-
ficient intervals to determine whether the infection is cured or whether
the parasites are simply sequestered.
Note that the model is fully capable of having an initial parasite
distribution that consists of multiple age classes, but to aid clarity, that
situation has not been shown in the simulations here.
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4.2.2.5. Full model
The full model is now presented, which couples a drug pharma-
cokinetic/pharmacodynamic model (Figure 4.22) with the parasite li-
fecycle/pharmacodynamic model introduced in the previous subsection
(Figure 4.18), but now with death rates coupled to the pharmacokinetic
model. Live and shadow compartments are also adopted in exactly the
same way to keep track of the amount of the drugs inside the red blood
cells.
The absorption compartments from the four compartment pharma-
cokinetic model, not relevant in the submodel above, are restored to the
full pharmacokinetic/pharmacodynamic model for in vivo use. The para-
site receptors and drugs inside parasites are now split into parasite age
classes, and use shadow compartments to facilitate what is essentially
the rotation of contents of these compartments when the parasites age.
Note that the parasitised red blood cell aspects of the drug model
are coupled to the lifecycle model, and the lifecycle model is coupled to
the drug concentration in parasitised red blood cells. The lifecycle model
triggers discrete events every 6 hours to toggle on the relevant shadow
flows, and discrete events are automatically triggered to toggle off the
zeroth-order shadow flows once the donor compartments become empty.
In between the discrete events, the model is described by a standard
system of coupled first-order ordinary differential equations.
The drug model is as simple as possible while still capturing all the
key features of the biological processes involved. As the study again
relates to orally administered artesunate (ARS) and its principle meta-
bolite dihydroartemisinin (DHA), the model is again divided into par-
ent/metabolite compartments with input to the parent absorption/gut
compartment.
As in the submodel, there are now compartments for red blood cells,
and parasites within some of those red blood cells, in addition to the
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oral doses u(t)
1. parent,
absorption
2. parent,
circulation
y1(t) = α1q2(t)
5. parent,
RBCs,
diffusion
6. metabolite,
RBCs,
diffusion
3. metabolite,
absorption
4. metabolite,
circulation
y2(t) = α2q4(t)
r1
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7.3
7.4
7.5
7.6
7.7
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7.d
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k31
k43
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k42
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k52(t)
k25(t)
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k46(t)
k65
ke,1 ke2
parasites inside RBCs
split by age class + shadowed
parasites inside RBCs
split by age class + shadowed
parasite receptors
facilitate transport
split by age class + shadowed
= parent drug (Artesunate), = active derivative and principle metabolite
(Dihydroartemisinin), = linear non-zero flow, = non-linear (i.e, non-constant
transfer coefficient). = coupled to parasite model.
Compartments 7.1–7.8, 8.1–8.8 and r1–r8 also have shadow copies but only the “initially live” set of
compartments is shown to prevent obscuring the more interesting aspects of the model.
N Figure 4.22: Diagram of drug model component. Note that shadow compart-
ments are also used here but are not shown to avoid obscuring the
rest of the diagram.
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plasma circulation compartments from the previous pharmacokinetic
model. Obviously each subject has a large number of red blood cells,
but for simplicity, the model only includes one red blood cell compart-
ment for each drug and one parasite compartment for each drug, and
thus captures only the average dynamics. The average quantities of drug
inside the red blood cells may therefore change during parasite death and
replication, but it is not felt that this affects the model utility.
Observations are made of the concentrations of ARS and DHA in
plasma (rather than in whole blood), and of the non-sequestered parasite
burden. While the drug concentrations are only measured in plasma in
the available datasets, representing whole blood distribution in the model
is more accurate than compensating for this through the observation gain
parameters as in subsection 2.6.1, and concentrations in the blood cells
are physiologically relevant. The remaining aspects of the model are ana-
logous to the corresponding respective components of the submodel and
previous pharmacokinetic model. Note that the model does not degener-
ate to the pharmacokinetic model in the case where there is no malaria,
due to the inclusion of the red blood cells with non-linear dynamics.
Distribution of ARS and DHA into uninfected cells is reversible, but
into infected cells is irreversible (due to conversion to free radical or
inactive and unmeasured forms, as confirmed when fitting the submodel
to the in vitro data); the red blood cells act as a sink for the drugs.
It is possible that metabolism of ARS to DHA will still occur to the
ARS present inside red blood cells. The model does not allow ARS to
metabolise once bound to the parasites, because this binding is irrevers-
ible and no further observations are made of either drug following such
binding, and so the model would not be able to support nor benefit from
such a metabolism parameter.
The initial conditions for the lifecycle component of the model, in-
cluding the initial time offset, are not known and have to be estimated.
Artesunate is administered orally, and initially enters impulsively at
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each dosing time into an absorption compartment. First-order irrevers-
ible absorption occurs into the systemic circulation (this compartment
lumps together multiple organs and blood, and has an apparent volume
of distribution). As in the submodel, the drug then undergoes passive
diffusion into red blood cells; this diffusion is reversible and driven by the
concentration gradient. At any of these stages, the drug can be meta-
bolised (hydrolysed) into the more active derivative dihydroartemisinin,
whence it can then undergo the remaining processes.
For subjects with malaria, both drugs are actively and irreversibly
transported into the parasite component of infected red blood cells. For
full model power, parasites (and hence drug in parasitised cells) are split
into 8 age classes. Once either drug derivative is inside a parasite, its
pharmacodynamic effect begins: parasites are killed, arrested or their
growth stunted. Once the pharmacodynamic effect has taken place, the
drug is no longer able to have any further effect — it is said to be de-
natured. In the model, this is represented by the drug flowing into its
respective denatured compartment, labelled 7.d and 8.d in the diagram.
These compartments are not strictly necessary as elimination from the
system model would be an equally valid modelling choice, but it may
be helpful to keep drug of the quantities of the drugs that have been
denatured to evaluate how significant this effective route of elimination
is.
Meanwhile, the parasites are progressing through their lifecycle:
ageing, replicating, and showing affects from the interaction with the
artemisinin derivatives. While a parasite matures (advances into the
next age class) after having taken up some artemisinin, the respective
amount of the artemisinin simultaneously moves into the respective age
class also. When a parasite dies, the artemisinin it contains flows into
the denatured/sink compartment. In order to prevent immediate further
maturation through the next class and so on, shadow compartments are
used. Essentially, there are two distinct copies of each compartment that
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is linked to a specific parasite stage.
The volumes of the red blood cell and parasite-bound drug compart-
ments are affected by the haematocrit and parasite burden at any par-
ticular time.
Uptake of drug into parasites of a particular age class requires avail-
ability of parasite receptors in that age class. This mechanism ensures
that uptake of drug into parasites is saturable. The differential equations
are therefore:
dq1
dt = −(k21 + k31 + ke,1)q1(t) + u(t)
dq2
dt = k21q1(t)− (k42 + ke2)q2(t) + k25(t)− k52(t)
dq3
dt = k31q1(t)− (k43 + ke3)q3(t)
dq4
dt = k42q2(t) + k43q3(t)− ke4q4(t) + k46(t)− k64(t)
dq5
dt = −
∑4
i=1
∑
x∈{lead,shadow} k7.x.i,5(t) + k52(t)− k25(t)− k65q5(t)
dq6
dt = −
∑4
i=1
∑
x∈{lead,shadow} k8.x.i,6(t) + k64(t)− k46(t) + k65q5(t)
dqr.x.i
dt = − 1ζ(t)(ka,ARS,iq5(t) + ka,DHA,iq6(t))qr.x.i(t) + fshadow,r.x.i(t)
dq7.x.i
dt = q5(t)ka,ARS,iqr.x.i(t) + fshadow,7.x.i(t)− d7.x.i(t)
dq8.x.i
dt = q6(t)ka,DHA,iqr.x.i(t) + fshadow,8.x.i(t)− d8.x.i(t)
(4.6)
where qr.x.i denotes the number of unbound parasite receptors for para-
sites in age class i, x is either the lead or shadow compartment, ka,j,i
denotes the uptake rate of drug j into a parasite in age class i.
To ensure the above equations are not unwieldly lengthy, the non-
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linear flows have been expressed as separate functions:
k52(t) = max
{
µARS(c2(t)− c5(t)), 0
}
(4.7)
k25(t) = max
{
µARS(c5(t)− c2(t)), 0
}
(4.8)
k64(t) = max
{
µDHA(c4(t)− c6(t)), 0
}
(4.9)
k46(t) = max
{
µDHA(c6(t)− c4(t)), 0
}
(4.10)
k7.x.i,5(t) =
ka,ARS,i
ζ(t) q5(t)qr.x.i(t) (4.11)
k8.x.i,6(t) =
ka,DHA,i
ζ(t) q6(t)qr.x.i(t) (4.12)
(4.13)
The parasite lifecycle is divided into 8 age stages of equal lengths,
reflecting the same divisions used in the drug model. The parasites ma-
ture into the next age class in continuous time. When progressing from
age class 8 to age class 1 to renew the lifecycle, a number of daughter
parasites are released, ready to infect more red blood cells. The model
assumes instant invasion of new red blood cells by the daughter parasites
(in reality, in non-anaemic patients, this re-invasion will take place within
the order of a few seconds, and so neglecting this is a reasonable model
simplification compared to the other time scales of interest). Where there
are insufficient red blood cells to invade, this could be reflected in the
model by reducing the number of daughter parasites produced, but all
patients are known to be non-anaemic here.
It is necessary to implement a threshold at which parasites are con-
sidered to be fully killed, otherwise recrudesence will always be experi-
enced due to the first-order kinetics.
Shadow compartments are used to ensure that parasites can only
mature through one age class at a time. For purposes not connected to
ageing, the number of parasites/drug in a particular state is the sum of
125
4. Model development and analysis
the two shadowing compartments for that state:
pi :=
∑2
x=1 px.i
qARS.i :=
∑2
x=1 qARS.x.i
qDHA.i :=
∑2
x=1 qDHA.x.i
qr.i :=
∑2
x=1 qr.x.i.
(4.14)
For stage i, the parasite death rate is
di(t) =
∑
j∈{ARS,DHA}
dj.i(t) (4.15)
where for convenience, the artemisinin derivatives are assumed to act
independently, with
dj.i(t) =
Emax,j.icj.i(t)
EC50,j.i +cj.i(t)
. (4.16)
Here, Emax,j.i controls the speed of parasite death in stage i caused by
drug j, cARS.i is understood to mean c7.i and cDHA.i to mean c8.i. As this
is non-linear with respect to the shadowing states, the shadowing states
are assumed to have contributed proportionally to the effect:
dj.x.i = −κdj.i(t) qj.x.i(t)
qj.1.i(t) + qj.2.i(t)
. (4.17)
Parasite death is assumed to be caused when all the receptors be-
longing to that parasite have bound to the artemisinins (though this is
not enforced by the model), so no further change needs to happen to the
number of available parasite receptors upon parasite death.
Continuous-time parasite ageing is realised through use of discrete
event toggles. It is assumed that the parasites within each age class are
roughly synchronised. The parasites’ lifecycle is known to have a dura-
tion of approximately 48 hours. Therefore, the ageing flows are toggled
every 6 hours. After 8 such toggles, the parasites will have matured
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through all 8 age classes and thus completed one full cycle. The timing
and duration of these discrete event toggles are deterministic and are not
influenced by other states of the model (though in reality it is hypothes-
ised that the artemisinins can delay parasite growth). After each toggle,
the shadow compartments and the lead compartments are swapped. In
the following, x denotes the complementary lead/shadow state to x. The
discrete events to toggle off the shadow flows are also deterministic but
their times are not known in advance, they are triggered when the relev-
ant state variables reaching zero.
While parasite ageing flows are activated, so too are the corresponding
flows for drugs inside the parasites and the number of parasite receptors,
with proportionate rates designed to ensure that the ageing process takes
the same duration to complete for each component. Parasite ageing
is described simply by linear zeroth-order flows during the activation
window.
dpi.x
dt = fshadow,p.i.x(t)− di.x(t) (4.18)
di.x = di(t)
pi.x(t)
pi.1(t) + pi.2(t)
. (4.19)
1s,x is an indicator flag for the shadow flows for x being activated.
When the model first runs, both 1s,1 and 1s,2 are zero. Once tlifecycle
reaches 12 hours, 1s,1 is set to 1. After the next 12 hours, 1s,1 is set to
0 and 1s,2 is set to 1. At this point, it should be the case that the states
with x = 1 will be virtually empty (otherwise the shadow flow rates are
set too small). This toggling of 1s,1 and 1s,2 then happens every 6 hours.
Most of the shadow flows have a similar structure, though may differ
in behaviour at the renewal of the cycle. During the reproduction phase
of the lifecycle, new parasite receptors are generated in proportion to the
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number of new parasites generated.
fshadow,p.x.i(t) =

1s,xMks,1,8px.8(t)− 1s,xks,i+1,ipx.i(t) i = 1
1s,xks,i,i−1px.i−1(t)− 1s,xks,i+1,ipx.i(t) i ∈ {2, . . . , 7}
1s,xks,i,i−1px.i−1(t)− 1s,xks,1,8px.i(t) i = 8
fshadow,r.x.i(t) =

1s,xκMks,8,1px.8(t) i = 1
1s,xκks,i,i−1qr.x.i−1(t)− 1s,xκks,i+1,iqr.x.i(t) i ∈ {2, . . . , 7}
1s,xκks,i,i−1qr.x.i−1(t)− 1s,xκks,1,8qr.x.i(t) i = 8
fshadow,7.x.i(t) =

−1s,xκks,i+1,iq7.x.i(t) i = 1
1s,xκks,i,i−1q7.x.i−1(t)− 1s,xκks,i+1,iq7.x.i(t) i ∈ {2, . . . , 7}
1s,xκks,i,i−1q7.x.i−1(t)− 1s,xκks,1,8q7.x.i(t) i = 8
dq7.d
dt =
∑8
i=1
∑2
x=1 di.x(t)q7.x.i(t) +
∑2
x=1 1s,xκks,1,8q7.x.8(t)
fshadow,8.x.i(t) =

−1s,xκks,i+1,iq8.x.i(t) i = 1
1s,xκks,i,i−1q8.x.i−1(t)− 1s,xκks,i+1,iq8.x.i(t) i ∈ {2, . . . , 7}
1s,xκks,i,i−1q8.x.i−1(t)− 1s,xκks,1,8q8.x.i(t) i = 8
dq8.d
dt =
∑8
i=1
∑2
x=1 di.x(t)q8.x.i(t) +
∑2
x=1 1s,xκks,1,8q8.x.8(t)
(4.20)
The shadowing rate parameters control the speed and synchronicity
of parasite ageing, and in particular, replication. In the above, M is the
parasite replication factor, which is considered constant.
Also during this phase, any drug that was previously inside the para-
site prior to replication is assumed to have no further effect on the daugh-
ter parasites (and is not released in active form into the bloodstream),
and so moves into the sink compartment.
4.2.2.6. Model parameters
For convenience, a table of all the parameters in the model is presented
in Table 4.7, while Table 4.8 provides a table of all the state variables and
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Table 4.9 lists all the intermediate functions used in the model equations.
Values for IC50 concentrations for ARS and DHA are available from
the literature [95] and may assist with identification and estimation of
them from the available data, though these are plasma concentrations
and not “within parasite” concentrations as used in this model.
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Parameter Description
k21 ARS absorption rate
k31 ARS to DHA metabolism rate prior to absorption
k42 ARS to DHA metabolism rate after absorption
k43 DHA absorption rate
ke,1 ARS elimination rate before absorption
ke2 ARS elimination rate from circulation
ke3 DHA elimination rate before absorption
ke4 DHA elimination rate from circulation
k65 ARS to DHA metabolism rate inside RBCs
ηj,i uptake rate of drug j into a parasite in age class i
µj RBC permeability (diffusion rate) for drug j
ka,j,i parasite-drug binding rate for drug j in age class i
α1 ARS quantity-concentration factor
α2 DHA quantity-concentration factor
k7.x.(j+1),7.y.j, j ∈ {1, 2, 3} shadow flow rate (toggled)
k7.x.d,7.y.4, j ∈ {1, 2, 3} shadow flow rate (toggled)
k8.x.(j+1),8.y.j, j ∈ {1, 2, 3} shadow flow rate (toggled)
k8.x.d,8.y.4, j ∈ {1, 2, 3} shadow flow rate (toggled)
kr.x.(j+1),r.y.j, j ∈ {1, 2, 3} shadow flow rate (toggled)
ke,r.y.j, j ∈ {1, 2, 3} shadow flow rate (toggled)
Emax,i,j maximum rate of parasite death in stage i from drug j
Table 4.7: Table of parameters for coupled model
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State Description
q1 quantity of ARS not yet absorbed into circu-
lation
q2 quantity of ARS in circulation
q3 quantity of DHA not yet absorbed into cir-
culation
q4 quantity of DHA in circulation
q5 quantity of ARS inside red blood cells (un-
bound)
q6 quantity of DHA inside red blood cells (un-
bound)
q7.x.i quantity of ARS bound to parasites in age
stage i and shadow state x
q8.x.i quantity of DHA bound to parasites in age
stage i and shadow state x
q7.d quantity of ARS that has denatured and is
no longer associated to a living parasite
q8.d quantity of DHA that has denatured and is
no longer associated to a living parasite
qr.x.i quantity of parasite receptors that is avail-
able for binding with the drugs, for parasites
in age stage i and shadow state x
px.i quantity of living parasites that are in age
state i and shadow state x
Table 4.8: Table of state variables used in the coupled
model
131
4. Model development and analysis
Function Description
c1 parent concentration prior to systemic circulation
c2 parent concentration in systemic circulation
c3 metabolite concentration prior to systemic circulation
c4 metabolite concentration in systemic circulation
c5 parent concentration in RBCs from passive diffusion
c6 metabolite concentration in RBCs from passive diffusion
c7.i.j parent concentration in infected RBCs from facilitated uptake
c8.i.j metabolite concentration in infected RBCs from facilitated uptake
t 7→ k52(t) parent drug passive duffusion into RBCs
t 7→ k25(t) parent drug passive duffusion from RBCs
t 7→ k64(t) metabolite passive duffision into RBCs
t 7→ k46(t) metabolite passive duffision from RBCs
t 7→ k7.i.j,5(t) parent drug uptake into infected RBCs in age stage j, shadow state i
t 7→ k8.i.j,6(t) metabolite uptake into infected RBCs in age stage j, shadow state i
t 7→ k7.d,7.i.j(t) parent drug flow when parasites die
t 7→ k8.d,8.i.j(t) metabolite drug flow when parasites die
t 7→ ke,r.i.j(t) parasite receptor flow when parasites die
y1 parent drug observation
y2 metabolite observation
pi total quantity of parasites in age class i
di rate of parasite death for parasites in age class i
Table 4.9: Table of intermediate functions used in the
coupled model
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4.2.3. Model simulation
As part of the model development process, simulations were obtained
to verify that the model has the intended behaviour, capturing the key
features it was intended to, and to verify that it describes the data to
the correct order of magnitude, without having any unanticipated or
unrealistic dynamics.
Model parameters were chosen so that the simulated curves peak at
roughly the same values as in Figure 4.1, and with an initial parasitaemia
of a typical order of magnitude as in the MORU_ARC3_PD dataset.
Naturally the model has many different parameters and input conditions
that can be manipulated (and were manipulated by the author during the
creation of this work), but a single simulation corresponding to one par-
ticular combination of parameters is shown here in Figure 4.23 to avoid
confusing the reader or overloading this thesis with largely repetitive
figures and descriptions. Some of these other possible model configura-
tions/conditions are discussed in conjunction with an evaluation of the
presented simulation. It should also be noted that for many of the fea-
tures observed in the simulation, different parameters may substantially
alter or eliminate those features: this is not a shortcoming of the model
but instead demonstrates its flexibility.
Plots of drug quantities in Figure 4.23 are shown in the same layout
as the respective compartments from Figure 4.22, except that only the
totals of the shadowed compartments are shown (as the shadowing is
only a modelling device and hinders rather than assists with a visual-
isation of the underlying system). For compartments where there is a
sensible interpretation of drug concentration, these are also indicated on
the same plots as the corresponding quantities, via use of dual y-axes: the
left-hand y axes represent quantities and the right-hand ones represent
concentrations. The haematocrit was taken to be constant so there is in
fact a constant volume for each of these compartments in this simulation.
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It is natural to take time t = 0 to be the timing of the first dose
as this is usually also when the observations of the parasitaemia begin
and the model would obviously not show any interesting dynamics be-
fore any drugs have been administered. In Figure 4.23, it can be seen
that the pharmacodynamic effect of the drugs starts to kill the parasites
almost immediately upon dosing of the artesunate at time 0, but does
not suddenly stop when the plasma concentrations of artesunate and di-
hydroartemisinin reach low levels. Indeed, a significant proportion of the
drugs enter into the parasites and remain there until either the parasites
die or the corresponding infected red blood cells burst. This is seen to be
more significant for DHA than it is for ARS, as expected due to the fast
conversion of ARS to DHA. By quantity, in this example, over 50% of
the ARS that reaches the systemic circulation is irreversibly taken up by
parasitised red blood cells. For DHA, the quantity in the parasitised cells
reaches more than double the peak quantity in the general circulation.
It is also readily seen that the model suggests that a single dose
of ARS may not be sufficient for full pharmacodynamic effect; the peak
ARS and DHA concentrations inside red blood cells are significantly lower
following the first dose than the second. Of course, the parasitaemia is
also lower by the time of the second dose, but the quantity of each drug
inside the parasitised cells is saturable and still increases again following
the second dose.
It is important to note that the volumes of distribution for ARS
and DHA represented in this model (corresponding to the circulation
compartments) are not comparable with volumes of distribution obtained
for malaria patients according to a model without a red blood cell or
parasitised cell uptake mechanism.
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It is also apparent from the time course of observed DHA concentra-
tions that the pharmacokinetics of at least DHA are significantly affected
by the severity and stage of the malarial infection, because the second
peak is much higher than the first. Hence in any multiple dosing study
involving DHA, capturing this effect requires a model such as this, with
coupling of the drug dynamics to the parasite burden. It is not reason-
able to conclude that ARS does not require such a complicated model,
because with other parameter values, similar behaviour is observed as for
DHA.
In producing this simulation, a single synchronous group of parasites
was specified, assumed to be 3 hours into their lifecycle at time t =
0. Hence, the parasites sequestered between t = 21 and 22 hours and
replicated between t = 45 and 46 hours. Parameters were set such that
the ageing and replication each took place over a period of one hour
duration. These transitions are also apparent from the model simulations
but are smooth gradual changes, not sharp sudden ones. Again the initial
population of parasites and the ageing durations/speed can be specified
differently in the model. For example, if the parasite population never
appears to dip and regrow, this may be specified with either parasites in
each of the age classes initially, with slower ageing transition times, or
with a faster rate of parasite kill. At time t = 45 hours, there is a small
but noticeable dip in the quantity of each drug that is present inside the
parasitised cells where the drug from ruptured red blood cells is modelled
as being effectively eliminated from the system, while simultaneously, the
drugs are being taken up into the newly parasitised red blood cells as the
parasites re-invade.
As has been reported for oral administration of ARS and noted in
chapter 2, the parasite burden is reduced 10,000-fold within one parasite
lifecycle period as seen in the plot of p(t). Though somewhat difficult to
observe from the figure due to the smooth transitions and confounding
from other factors, the rate of parasite kill also varies with time due to
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the stage-specific effects, which were set to have a susceptibility weight
of 0.5 for the first 6 hours of the parasite lifecycle, 1 for the next 30 hours
(until the parasites sequester) and then 0.1 for the remaining 12 hours
for illustrative purposes.
As mentioned in subsection 2.3.3, this model was designed with stud-
ies in mind that included a third dose of ARS on day three, but the model
behaviour following this third dose was essentially identical to that of the
second, and so a 72 hour time window is shown excluding the third dose
to better illustrate the model behaviour upon parasite replication once
treatment has finished. It is therefore clear that if insufficient doses of
ARS are administered, then the illness may recrudesce.
In summary, the model demonstrates all the expected and desired
features as intended and has many parameters available for tuning the
behaviour as applicable to each particular subject/patient.
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Chapter 5
Closing
5.1. Conclusions and future work
It was not possible to meet all the aims and objectives set out in sec-
tion 1.2, but the main aim was to develop a novel pharmacokinetic and
pharmacodynamic model to capture important properties of artemisinin-
based treatments, and indeed such a model has been proposed and shown
to be viable.
New methods have been developed to help analyse this model, though
not all these methods were able to successfully applied within the time
constraints of the project, and some of the new methods designed were
ultimately not applicable to the final version of the model structure and
were therefore not presented here as it would have disrupted the focus
on the overall aim.
The in vitro model has been shown to be structurally globally identi-
fiable and describes the radio-labelled data reasonably well, although the
parameters are not able to simultaneously describe all the in vitro data
to the same level of accuracy, but the overall shape is generally captured.
Due to the discrete events within the model, it is not possible to ana-
lyse it from a structural identifiability perspective as a complete unit,
but it is possible to consider the behaviour of the model up until the
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first discrete event (though this clearly will not be able to inform on
the identifiability of the discrete event times, which will require practical
identifiability analyses). The author has applied structural identifiabil-
ity methods to the model in this setting but these have so far proved
intractable, probably due to the complexity of the model in terms of the
number of parameters, number of state variables, and the nature of the
non-linearities. It might be possible to proceed under the assumption
that more of the parameters are known, or by deriving necessary and
sufficient conditions for some of the parameters by analysing submodels
of the full model. Further or alternatively, consideration of numerical and
practical identifiability should be more straight-forward (but require for-
ward simulations of the full model). Though these are also computation-
ally demanding, which is why no results have been successfully obtained
so far, numerical and practical identifiability have the advantage that
sufficient computation time is really the only ingredient needed for such
an analysis, whereas structural identifiability using algebraic methods is
in some sense a “black box” because the symbolic algebra package does
the calculations and the progress cannot be inferred, nor the intermedi-
ate results displayed or used. Eventually, often after a period of a few
days, the symbolic algebra system will run out of memory (even if the
problem is assigned to a highly specified and otherwise capable server)
and the entire calculation will be terminated, leaving no usable evidence
of any progress towards a solution.
The SMC method described in this work has been demonstrated on
a small selection of models, including low dimensional models to explore
and illustrate the typical behaviour in various situations, and also on
the four compartment model introduced in previous work. Though not
entirely straightforward, the method can be adjusted to run in parallel
on modern computing clusters [85, 96, 97, 98], which could speed up the
use of SMC considerably.
It is seen that the assumption of normally distributed errors is perhaps
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not the most appropriate, since there are many outliers in the model fits
which are heavily punished under this error model. A distribution with
heavier tails such as Laplace or Student’s t-distribution would be worth
considering.
Finally, a simulation from the full coupled pharmacokinetic and phar-
macodynamic drug-parasite model was presented and discussed, and it
was demonstrated that the model met the overall aims (with the argu-
able exception of simplicity in an absolute sense, but necessary given the
complexity of the real world system it attempts to represent). Imple-
mentation of the model in a more user-friendly package that the reader
could interact with would potentially alleviate some of the negative ef-
fects of the model complexity. Simulations generated according to the
full coupled model could be produced within a few seconds for most
parameter combinations (but took up to 2 hours for others), though no
attempt was yet made to optimise this. The time that would there-
fore be required to generate forward model evaluations for use in SMC
likelihood calculations may therefore be concerning, but hopefully with
optimisation and improved computational facilities that have been de-
veloped since the author started this work, would be well within the
limits of present feasibility. This might permit eventual fulfilment of the
remaining objective of using the model and methods described herein to
perform inference for clinically-obtained data.
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